Wissenschaftliche Veröffentlichungen – Hamburger Zentrum für Kinder- und Jugendrheumatologie

Orginalberichte

S. Lederman, J.A. DeMartino, B.L. Daugherty, I. Foeldvari, M.J. Yellin, A.M. Cleary, N. Berkowitz, I. Lowy, N.S. Braunstein, G.E. Mark and L. Chess: A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol.Immunol.1991; 28 (11): 1171-1181. – Impact factor- 2,98
I. Foeldvari, R.A. Cairns, R.E. Petty, D.A. Cabral: An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: A case report. Clin Exp Rheumatol 1995;13 : 525-8.- – Impact factor- 2,4
I. Foeldvari, E. Waida, A. K. Junker: Systemic capillary leak syndrome in a child. A case report. J Pediatrics 1995; 127: 739-41. – Impact factor- 4,042
I. Foeldvari, A. Wuesthof: Delayed diagnosis of juvenile rheumatoid arthritis in a girl with Turner Syndrome. Clin Exp Rheum 1997,15:701-3. – Impact factor- 2,4
I. Foeldvari, M. Schmitz: Rapid development of a severe osteoarthritis associated with osteoid osteoma in a young girl. Clinical Rheumatology 1998, 17:534-7. – Impact factor- 1,283
I. Foeldvari, M. Birdi: Validation of the proposed Durban classification criteria for juvenile idiopathic arthritis in the patient population of the pediatric rheumatology clinic in Hamburg, Germany. J Rheumatol 2000, 27:1069-72. – Impact factor- 3,551
I. Foeldvari, M. Zhavania, N. Birdi, P.B. Dent, R. Elborgh, F. Falcini, H Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian: Favourable outcome in 135 children with juvenile systemic sclerosis (jSSc): Results of a multinational survey. Rheumatology 2000,39:556-9. – Impact factor- 4,171
P.H. Hoeger, N. Veelken, I. Foeldvari: Neonatal onset of rash in Still´s disease. Journal of Pediatrics 2000; 137:128-31. – Impact factor- 4,042
I. Foeldvari, A. Thon, R. Burgos-Vargas: Studienergebnisse zum COX-2-Hemmer Meloxicam. Rheuma aktuell 2000, 4/00:14-16. – Impact factor- NN
J. M. Maerker, A. Harm, I. Foeldvari, P.H. Hoeger: Naproxen-induzierte Pseudoporphyrie. Hautarzt, 2001,52:1026-9. – Impact factor- 0,451
I.Foeldvari, N. Ruperto, F. Dressler, R. Häfner, R.M. Küster, H.Michels, K.Minden, C. Schauer-Petrowskaja, M.Bullinger, J.M.Landgraf, H.I. Huppertz, for the Paediatric Rheumatology International Trials Organisation (PRINTO): The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001, 19 Suppl 23:S 71- S 75. – Impact factor- 2,4
I. Foeldvari, R. Burgos-Vargas, A. Thon,D.Tuerck: High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol 2002; 29: 1079-83. – Impact factor- 3,551
I. Foeldvari, C. Thiel, M. Eiselt, J. Weil: Juvenile spondyloarthritis and severe cardiac involvement. In a female paient. J. Rheumatol 2003, 30: 1087-9. – Impact factor- 3,551
K. Meyer, I. Foeldvari, R.M. Küster, L. Huck, B. Kahl-Nieke: Das Kiefergelenk bei juveniler idiopathischer Arthritis. Zahnärztliche Welt Rundschau. Das deutsche Zahnärzteblatt 2003, 112: 64- 74. – Impact factor- NN
I. Foeldvari. Pediatric Rheumatology in Germany: A new model to set up a pediatric rheumatology service in Germany. Pediatric Rheumatology online Journal 2004,Vol 2. No.2. – Impact factor- 1,74
R. Burgos Vargas, I. Foeldvari, A. Thon.,R. Linke, D Tuerck: Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. Journal of Clinical Pharmacology 2004; 44: 866-872.- Impact factor- 3,59
G. Horneff, H. Schmeling, T. Biedermann, I. Foeldvari, G. Ganser, HJ. Girchick, T. Hospach, HI. Huppertz,R. Keitzer, RM: Küster, H. Michels, D. Moebius, B. Rogalski, A. Thon for the Pediatric Rheumatologiy Collaborative Group. The German Etnercept registry for treatment of juvenile idiopathic arthritis. Annals of Rheumatic Diseases 2004; 63: 1638-44. Impact factor-9,082
Nicolino Ruperto, 2Nina Kuzmina, 3Evgueni D. Pachanov, 4Ynessa Shachbazian, 5Richard Mouy, 6Rik Joos, 7Francesco Zulian, 8Rudolf Schwarz, 9Valeria Artamonova, 10Walter Emminger, 1Marcia Bandeira, 1Antonella Buoncompagni, 11Ivan Foeldvari, 12Fernanda Falcini, 13Eileen Baildam, 14Isabelle Kone-Paut, 15Mariolina Alessio, 16Valeria Gerloni, 17Alessandro Lenhardt, 1Alberto Martini, for the Paediatric Rheumatology International Trials Organisation (PRINTO), 18Gertraud Hanft, 18Ralf Sigmund, 18Stefan Simianer. A randomized, double-blind clinical trial of two doses of meloxicam compared to naproxen in juvenile idiopathic arthritis: short and long term efficacy and safety results. Arthritis Rheum 2005;52:563-572. Impact factor- 8,435
I Foeldvari , A Wierk. Methotrexat is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J.Rheumatology 2005; 32: 362-366. Impact factor- 3,551
D. E. Furst, D Khanna,M Mattucci-Cerinic, A Sillman, P.A. Merkel and I Foeldvari. Report of the Scleroderma – Developing measures of response. J Rheumatol 2005. 32: 2477-80. Impact factor – 3,551
I. Foeldvari, A. Wierk: Healthy children have a significantly increased skin score assessed with the modified rodnan skin score. Rheumatology 2006, 45: 76-78. Impact factor 4,171
Francesco Zulian, Balu H Athreya, Ronald Laxer, Audrey M Nelson, Sheila Knupp Feitosa de Oliveira, Marilynn G Punaro, Ruben Cuttica, Gloria C Higgins, Lisette W.A. Van Suijlekom-Smit, Terry L Moore, Carol Lindsley, Julia Garcia Consuegra, Maria Odete Esteves Hilário, Loredana Lepore, Clovis A Silva, Claudia Machado, Stella M Garay, Yosef Uziel, Giorgia Martini, Ivan Foeldvari, Andrea Peserico, Patricia Woo and John Harper, for the Juvenile Scleroderma Working Group of the Pediatric: Juvenile Localized Scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology 2006, 45: 614-620. Impact factor- 4,171
D.A. Cabral, R.M. Laxer, J. Schrader , S. Turvey, A. Stevens, R.S.M. Yeung, H.E. Forster, H. Emery. J. Premdiville, L.B. Tucker, I. Foeldvari, D.D. Sherry, A.B. Klinkhoff, C.A. Wallace, K. Houghton. Old challenges and new directions in pediatric rheumatology. J Rheumatol 2006, 33: 173-84. Impact factor- 3,551
C. Boschan, O. Witt, L. Schweigerer, P. Lohse, I. Foeldvari, H. Zappel. Neonatal- onset multisystem inflammatory disease (NOMID): new mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. American Journalo of Medical Genteics 2006;140 A: 883-6. Impact factor- 2,505
O. Distler, F. Behrens, D. Huscher, I. Foeldvari, A. Zink, P. Nash, C. Denton, M. Humbert, M. Matucci-Cerinic, J. Seibold, L. Rubin, D. Furst. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis Rheumatology 2006, 45: 1455-7. Impact factor- 4,171
Giorgia Martini1, Ivan Foeldvari2, Ricardo Russo3, Ruben Cuttica4, Anne Eberhard5, Angelo Ravelli6, Thomas H Lehman7, Sheila Knupp Feitosa de Oliveira8, Gordana Susic9, GA Lyskina10, Dana Nemcova11, Robert Sundel12, Fernanda Falcini13, Herman Girschick14, Ana Paula Lotito15, Antonella Buoncompagni6, Flavio Sztajnbok16, S Al-Mayouf17, Orban Ilonka18, Clodoveo Ferri19, Balu H Athreya20, Patricia Woo21 and Francesco Zulian1 for the Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Systemic Sclerosis in childhood: clinical and immunological features of 153 patients. An international database Arthritis and Rheumatism 2006, 54:3971-8. Impact factor- 8,435
K. Minden, M. Niewerth, G. Ganser, I. Foeldvari, A. Thon, A Zink : Die Kerndokumentation rheumakranker Kinder und Jugendlicher. Kinder- und Jugenmedizin 2006;6: 312-7. Impact factor- NN
Sheila Oliveira,1 Angelo Ravelli,1 Angela Pistorio,2 Esteban Castell,1 Clara Malattia,3 Anne Marie Prieur,4 Claudia Saad-Magalhães,5 Kevin J. Murray,6 Sang-Cheol Bae,7 Rik Joos,8 Ivan Foeldvari,9 Carolina Duarte,10 Nico Wulffraat,11 Pekka Lahdenne,12 Pavla Dolezalova,13 Jaime de Inocencio,14 Polyxeni Pratsidou-Gertsi,15 Michael Hofer,16 Irina Nikishina,17 Huri Ozdogan,18 Phil Hashkes,19 Alberto Martini,20 Nicolino Ruperto,1 for the Pediatric Rheumatology International Trials Organisation (PRINTO). Proxy-reported Health related Quality of Life of patients with juvenile idiopathic arthritis. The PRINTO multinational quality of life cohort. Arthritis and Rheumatism 2007, 57:35-43. Impact factor- 8,435
I. Foeldvari, S. Nielson, K. Rothe, J. Kümmerle-Deschner, G. Espada, G. Horneff, B. Blanca, .A. Oliviere, C.le Blanc, M. Fischbach, S. Grayay, M. Henrickson, M.M. Katsikas, K.O´Neil, J.P. Whelan, A. Wierk, T. Saurenmann. Tumor Necrosis Factor- alfa in the treatment of juvenile idiopathic arthritis associated uveitis refractory to second line agents: Results of a multinational survey. Journal of Rheumatology 2007, 34: 1146-50. Impact factor- 3,551
Francesco Zulian,1 Patricia Woo,2 Balu H Athreya3 Ronald M Laxer4, Thomas A. Medsger Jr,5 Thomas H Lehman,6 Marco Matucci Cerinic,7 Giorgia Martini,1 Angelo Ravelli,8 Ricardo Russo,9 Ruben Cuttica,10 Sheila Knupp Feitosa de Oliveira,11 Christofer Denton,12 Franco Cozzi,13 Ivan Foeldvari,14 Nicolino Ruperto8 for the Pediatric Rheumatology European Society (PRES). The Pediatric Rheumatology European Society/American Collerge of Rheumatology/ European League Against Rheumatism Provisional classification criteria for systemic sclerosis. Arthritis and Rheumatism 2007: 57:203-212. Impact factor- 8,435
Daniel Furst, Dinesh Khanna, Marco Matucci-Cerinic, Philip Clements, Virginia Steen, Janet Pope, Peter Merkel, Ivan Foeldvari, James Seibold, David Pittrow, Vibeke Strand, Richard Polisson Systemic Sclerosis – Continuing Progress in Developing Clinical Measures of Response, OMERACT 2006. J. Rheumatol 2007;34:1994-1200. Impact factor- 3,551
U.A. Walker, A. Tyndall, L. Czirjak,….. I. Foeldvari 98, ….. Clinical risk assessment of organ manifestation in systemic sclerosis: a report from the EULAR scleroderma trials an research group database. Ann Rheum Dis 2007, 66: 754-63. Impact factor- 9,082
N Ruperto, A Ravelli, A Pistorio, V. Ferriani, PISTORIO, I Calvo, G Ganser, J Brunner, G Dannecker, CA Silva , V Stanevicha, R ten Cate, L W. A. Van Suijlekom-Smit, O Voygioyka, M Fischabach, I Foeldvari, et al. For the Peadiatrich Rheumatology Internation Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) . The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease Activity Core Set for the Evaluation of Response to Therapy in Juvenile Dermatomyositis: A Prospective Validation Study. Arthritis Rheumatism 2008, 59: 4-13. Impact factor- 8,435
Oliver Distler1, Frank Behrens2, David Pittrow3, Doerte Huscher4, Christopher P Denton5, Ivan Foeldvari6, Marc Humbert7, Marco Matucci-Cerinic8, Peter Nash9, Christian Opitz10, Lew Rubin11, Jim Seibold12 and Daniel E. Furst13 for the other coauthors of the EPOSS-OMERACT group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphi consensus study with cluster analysis . Arthritis Care & Research, 2008; 59:867-75. Impact factor- 4,749
Daniel J. Lovell, M.D., M.P.H., Nicolino Ruperto, M.D., M.P.H., Steven Goodman, M.D., Andreas Reiff, M.D., Lawrence Jung, M.D., Katerina Jarosova, M.U.Dr., Dana Nemcova, M.D., Anne-Marie Prieur, M.D., Christy Sandborg, M.D., John Bohnsack, M.D., Dirk Elewant, M.D., Ivan Foeldvari, M.D., Valeria Gerloni, M.D., Jozef Rovensky, M.D., Ph.D., Kirsten Minden, M.D., R. Vehe, M.D., L. Wagner Weiner, M.D., Gerd Horneff, M.D., Hans-Iko Kuppertz, M.D., G. N. Olson, M.D., John R. Medich, Ph.D., Roberto Carcereri-De-Prati, M.D., Melissa J. McIlraith, Ph.D., Edward H. Giannini, M.Sc., Dr.P.H., and Alberto Martini, M.D., for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Pediatric Rheumatology International Trials Organisation (PRINTO). Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. NEJM 2008; 359:810-820. Impact factor- 8,41
Khanna D, Lowell DJ, Ginannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denot CP, Mayes MD, Steen VD, Varga J, Furst DE for the Scleroderma Clinical Trial Consortium coauthors…. Foeldvari I……. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703-9. Impact factor- 8,435
N. Hunzelmann 1, E. Genth2, T. Krieg1, W. Lehmacher3, I. Melchers4, M. Meurer5, P. Moinzadeh1, U. Müller-Ladner 6, C. Pfeiffer5, G. Riemekasten7, E. Schulze-Lohoff 8, C. Sunderkoetter9, M. Weber8, M. Worm 10, P. Klaus10, A. Rubbert11, K. Steinbrink12, B. Grundt12, R. Hein13, K. ScharffetterKochanek 14, R. Hinrichs14, K. Walker14, R.-M. Szeimies15, S. Karrer15,A.Müller16, C. Seitz17, E. Schmidt 17, P. Lehmann18, I. Foeldvari19, F. Reichenberger20, W. L. Gross21, A. Kuhn22, M. Haust22, K. Reich 23,M.Böhm9, P. Saar16, G. Fierlbeck24,I.Kötter25, H.-M. Lorenz26, N. Blank26, K. Gra ¨ fenstein 27, A. Juche27, E. Aberer28, G. Bali28, C. Fiehn29, R. Stadler30 and V. Bartels30. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008; 47: 1185-1192. Impact factor- 4,171
Horneff, G. De Bock, F. Foeldvari, I. Girschick, H. J., Michels, H. Moebius, D. Schmeling, H. : Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009, 68:519-25. Imapct factor 9,087
Kowal-Bielecka O (1) Landewé R (2), Avouac J (3), (3), Chwiesko S (1), Miniati I (4), Czirjak L (5), Clements P (6), Denton C (7), Farge D (8), Fligelstone K (9), Földvari I (10), Furst DE (6), Müller-Ladner U (11), Seibold J (12), Silver RM (13), Takehara K (14), Garay Toth B (15), Tyndall A (16), Valentini G (17), van den Hoogen F (18), Wigley F (19), Zulian F (20), Matucci-Cerinic M (4) and EUSTAR coauthors*. EULAR/EUSTAR Recommendations for the Treatment of Systemic Sclerosis. Ann Rheum Dis 2009, 68:620-628. Impact factor- 9,087
Ivan FOELDVARI, ILONA S. SZER, LAWRENCE S. ZEMEL, DANIEL J. LOVELL, EDWARD H. GIANNINI, JEFFREY L. ROBBINS, CHRISTINE R. WEST, GINA STEIDLE, SRIRAM KRISHNASWAMI, and BRADLEY J. BLOOM. A Prospective Study Comparing Celecoxib With Naproxen in Children With Juvenile Rheumatoid Arthritis. J Rheumatol 2009, 36: 174-182. Impact factor- 3,551
Avouac J, Kowal-Bielecka O, Landewe R, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foeldvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM; Takehara K, Garay Toth B, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M and EUSTAR coauthors. European League against Rheumatism (EULAR) Scleroderma Trial and Research Group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of the systemic literature research. Ann Rheum Dis 2009,68: 629- 634. Impact factor- 9,087
Horneff G , Ebert A , Fitter S , Minden K , Foeldvari I , Kümmerle-Deschner J , Thon A , Girschick HJ , Weller F , Huppertz HI. Safety and efficacy of once weekly Etanercept 0.8 mg/kg in a multicentre 12 weeks trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 2009;48:916-919. Impact factor- 4,17
Horneff G De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, for the the German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis: preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68: 519-25. Impact factor- 9,087
Dinesh Khanna*, Oliver Distler*, F Behrens , Philip Clements, Christopher Denton, Edward Giannini, Doerte Huscher , Ivan Foeldvari , Daniel Lovell, Marco Matucci-Cerenic, Maureen Mayes, Peter Merkel, Peter Nash, C Opitz, David Pittrow, Lewis Rubin, James Seibold, Virginia Steen, Vibeke Srand, Peter Tugwell, John Varga, Angela Zink and Daniel E.Furst** for the investigators in CRISS and EPOSS(*co-first authors;**Senior author; all other cited authors in alphabetical order). Measures of Response in Clinical Trials of Systemic Sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in PAH Related to Systemic Sclerosis (EPOSS). J Rheumatol 2009,36:2356-61. Impact factor- 3,551
Jérôme Avouac* (1), Otylia Kowal-Bielecka* (2), David Pittrow (3), Doerte Huscher (4), Frank Behrens (5), Christopher P Denton (6), Ivan Foeldvari (7), Marc Humbert (8), Marco Matucci-Cerinic (9), Peter Nash (10), Christian F. Opitz (11), Lewis J. Rubin (12), James R. Seibold (13), Oliver Distler * (14) and Daniel E. Furst * (15) for the EPOSS group *contributed equally. Validation of the six-minute walk test according to the OMERACT filter: a systematic literature review. Ann Rheum Dis 2010, 69: 1360-3. Impact factor- 9,087
Nicolino Ruperto, M.D., M.P.H.; Daniel J. Lovell, M.D., M.P.H.; Ruben Cuttica, M.D.; Patricia Woo, M.D., Prof.; Silvia Meiorin, M.D.; Carrie Wouters, M.D. PhD.; Earl D. Silverman, M.D.; Zsolt Balogh, M.D.; Michael Henrickson, M.D.; Joyce Davidson, M.D.; Ivan Foeldvari, M.D.; Lisa Imundo, M.D.; Gabriele Simonini, M.D.; Joachim Oppermann, M.D.; Yaung-Kaung Shen, Ph.D.; Sudha Visvanathan, PhD, Adedigbo Fasanmade PhD, Alan Mendelsohn, M.D., FACC; Alberto Martini, M.D.; Prof., Edward H. Giannini, M.Sc., Dr.P.H., for the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69: 718-22. Impact factor- 9,087
Otylia Kowal-Bielecka1*, Jerome Avouac2*, David Pittrow3, Doerte Huscher4, Frank Behrens5, Christopher P Denton6, Ivan Foeldvari7, Marc Humbert8, Marco Matucci-Cerinic9 Peter Nash10, Christian F. Opitz11, Lewis J Rubin12, James R. Seibold13, Vibeke Strand14, Daniel E Furst15*, Oliver Distler16*, for the EPOSS group. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010, 37:105-15. Impact factor- 3,551
Iris Vilca1*, Pablo Garcia Munitis1*, Angela Pistorio2, Angelo Ravelli3, Antonella Buoncompagni1, Blanca Bica4, Lucia Campos5, Renate Hafner6, Michael Hofer7, Seza Ozen8, Christian Huemer9, Sang Cheol Bae10, Flavio Sztajnbok11, Olga Arguedas1, Ivan Foeldvari12, Hans Iko Huppertz13, Mari Luz Gamir Gamir14, Bo Magnusson15, Frank Dressler16, Josef Uziel17, Renée van Soesberger18, Peter Hollingworth19, Gail Cawkwell20, Alberto Martini3, Nicolino Ruperto1 for the Pediatric Rheumatology International Trials Organisation (PRINTO). Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathich arthritis: analysis of the PRINTO methotrexate trial. Annals of Rheumatic Diseases. 2010;69:1479-1483. Impact factor- 9.087
Dirk Foell, M.D., Nico Wulffraat, M.D., Lucy Wedderburn, M.D., Helmut Wittkowski, M.D., Michael Frosch, M.D., Joachim Gerß, Ph.D., Valda Stanevicha, M.D., Dimitrina Mihaylova, M.D., Virginia Ferriani, M.D., Florence Kanakoudi Tsakalidou, M.D., Ivan Foeldvari, M.D., Ruben Cuttica, M.D., Benito Gonzalez, M.D., Angelo Ravelli, M.D., Raju Khubchandani, M.D., Sheila Oliveira, M.D., Wineke Armbrust, M.D., Stella Garay, M.D., Jelena Vojinovic, M.D., Ximena Norambuena, M.D., María Luz Gamir, M.D., Julia Garcia Consuegra, M.D., Loredana Lepore, M.D., Gordana Susic, M.D., Fabrizia Corona, M.D., Pavla Dolezalova, M.D., Angela Pistorio, M.D., Ph.D.,Alberto Martini, M.D., Nicolino Ruperto, M.D., M.P.H., Johannes Roth, M.D., for the Paediatric Rheumatology INternational Trials Organization (PRINTO). Myeloid-Related Proteins 8 and 14 (MRP8/14) as biomarker for a risk-adapted treatment duration in juvenile idiopathic arthritis: Results of a randomized trial of 6 versus 12 months withdrawal of methotrexate. JAMA 2010, 303(13):1266-1273. Impact factor- 30,0
Ivan Foeldvari and Angela Wierk. Effectiveness of Leflunomide in Patients with Juvenile Idiopathic Arthritis in Clinical Practice. J Rheumatol 2010, 37.1763-7. Impact factor- 3,551
Nicolino Ruperto, Daniel J Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Pérez, Clovis A Silva, Carlos Abud-Mendoza7, Ruben Burgos-Vargas,Valeria Gerloni, Jose A Melo-Gomes, Claudia Saad-Magalhães, J Chavez, Christian Huemer, Alan Kivitz, Francisco J Blanco, Ivan Foeldvari, Michael Hofer, Gerd Horneff, Hans-Iko Huppertz, Chantal Job Deslandre, Anna Loy, Kirsten Minden, Marilynn Punaro, Alejandro Flores Nunez, Leonard H Sigal, Alan J Block, Marleen Nys, Alberto Martini, Edward H Giannini, for the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. Arthritis Rheum 2010 Volume 62 Issue 6, Pages 1792 – 1802. Impact factor. 8,435
Doerte Huscher1*, David Pittrow2*, Oliver Distler3, Christopher P Denton4, Ivan Foeldvari5, Marc Humbert6, Marco Matucci-Cerinic7, Otylia Kowal-Bielecka8, Jerome Avouac9, Frank Behrens10, Peter Nash11, Christian F. Opitz12, Lewis J Rubin13, James R. Seibold14 and Daniel E. Furst15 for the other coauthors of the EPOSS-OMERACT group† Interactions between rheumatologistst and cario-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clinical and Experimental Rheumatology 2010, 28: 2 Suppl 58:S47-52. Impact factor- 2,4.
Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR, Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabrielli A, Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S, Reich K, Bombardieri S, Siakka P, Pellerito R, Bambara LM, Morovic-Vergles J, Denton C, Hinrichs R, Van den Hoogen F, Damjanov N, Kötter I, Ortiz V, Heitmann S, Krasowska D, Seidel M, Hasler P, Van Laar JM, Kaltwasser JP, Foeldvari I, Juan Mas A, Bajocchi G, Wislowska M, Pereira Da Silva JA, Jacobsen S, Worm M, Graniger W, Kuhn A, Stankovic A, Cossutta R, Majdan M, Damjanovska Rajcevska L, Tikly M, Nasonov EL, Steinbrink K, Herrick A, Müller-Ladner U, Dinc A, Scorza R, Sondergaard K, Indiveri F, Nielsen H, Szekanecz Z, Silver RM, Antivalle M, Espinosa IB, García de la Pena Lefebvre P, Midtvedt O, Launay D, Valesini F, Tuvik P, Ionescu RM, Del Papa N, Pinto S, Wigley F, Mihai C, Sinziana Capranu M, Sunderkötter C, Jun JB, Alhasani S, Distler JH, Ton E, Soukup T, Seibold J, Zeni S, Nash P, Mouthon L, De Keyser F, Duruöz MT, Cantatore FP, Strauss G, von Mülhen CA, Pozzi MR, Eyerich K, Szechinski J, Keiserman M, Houssiau FA, Román-Ivorra JA, Krummel-Lorenz B, Aringer M, Westhovens R, Bellisai F, Mayer M, Stoeckl F, Uprus M, Volpe A, Buslau M, Yavuz S, Granel B, Valderílio Feijó A, Del Galdo F, Popa S, Zenone T, Ricardo Machado X, Pileckyte M, Stebbings S, Mathieu A, Tulli A, Tourinho T, Souza R, Acayaba de Toledo R, Stamp L, Solanki K, Veale D, Francisco Marques Neto J, Bagnato GF, Loyo E, Toloza S, Li M, Ahmed Abdel Atty Mohamed W, Cobankara V, Olas J, Salsano F, Oksel F, Tanaseanu CM, Foti R, Ancuta C, Vonk M, Caramashi P, Beretta L, Balbir A, Chiàla A, Pasalic Simic K, Ghio M, Stamenkovic B, Rednic S, Host N, Pellerito R, Hachulla E, Furst DE. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010 ;37:148. Impact factor- 3,551.
Ivan Foeldvari, Svetlana I. Nihtyanova2, Angela Wierk, Chris Denton. Characteristics of juvenile onset systemis sclerosis patients in an adult single centre cohort. Concise report. J Rheumatol 2010; 37:2422–6. Impact factor- 3,551
G. Horneff, I. Foeldvari, K. Minden, , T. Hospach, Moebius Report on Malignancies in the German Juvenile Idiopathic Arthritis Registry.Rheumatology 2011;50:230-6. Impact factor- 4,171
A.F. Jansson1, C. Sengler, J. Kuemmerle-Deschner, B. Gruhn4, B. Kranz, H. Lehmann6, B. Kleinert, L. Pape, D. Moebius, J. Peitz, D. Foell, H.J. Girschick, I. Foeldvari, J.P. Haas, D Haffner, V. Grote. B- cell depletion for autoiummune disease in pediatric patients. Clinical Rheumatology 2011, 30:87-97. Impact factor- 1,283
Christopher P Denton, Jerome Avouac, Frank Behrens, Daniel E Furst, Ivan Foeldvari, Marc Humbert, Doerte Huscher, Otylia Kowal-Bielecka, Marco Matucci-Cerinic, Peter Nash, Christian F Opitz, David Pittrow, Lewis J Rubin, James R Seibold and Oliver Distler. Systemic sclerosis associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research & Therapy 2011,13: 114. Impact factor- 4,27
Rudolf Mierau1, Pia Moinzadeh2, Gabriela Riemekasten3, Inga Melchers4, Michael Meurer5, Frank Reichenberger6, Michael Buslau7, Margitta Worm8, Norbert Blank9, Rüdiger Hein10, Ulf Müller-Ladner11, Annegret Kuhn12,13, Cord Sunderkoetter13, Aaron Juche14, Christiane Pfeiffer 15, Christoph Fiehn16, Michael Sticherling17, Percy Lehmann18, Rudolf Stadler19, Eckhard Schulze-Lohoff20, Cornelia Seitz21, Ivan Foeldvári22, Thomas Krieg2, Ekkehard Genth23, and Nicolas Hunzelmann2. Frequency of disease associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Research and Therapy. 2011 13: R 172. Impact factor- 4,27
Dueckers Gregor*, Guellac Nihal*, Arbogast Martin, Dannecker Guenther, Foeldvari Ivan, Frosch Michael, Ganser Gerd, Heiligenhaus Arnd, Horneff Gerd, Illhardt Arnold, Kopp Ina, Krauspe Ruediger, Markus Barbara, Michels Hartmut, Schneider Matthias, Singendonk Wolfram, Sitter Helmut, Spamer Marianne, Wagner Norbert, Niehues, Tim. Evidence and consensus based GKJR guidelines 2010 for the treatment of juvenile idiopathic Arthritis (JIA) Klinische Pädiatrie 2011, 223: 386-94. Impact factor- NN
Dueckers Gregor*, Guellac Nihal*, Arbogast Martin, Dannecker Guenther, Foeldvari Ivan, Frosch Michael, Ganser Gerd, Heiligenhaus Arnd, Horneff Gerd, Illhardt Arnold, Kopp Ina, Krauspe Ruediger, Markus Barbara, Michels Hartmut, Schneider Matthias, Singendonk Wolfram, Sitter Helmut, Spamer Marianne, Wagner Norbert, Niehues, Tim. Evidence and consensus based GKJR guidelines 2010 for the treatment of juvenile idiopathic Arthritis (JIA) Clinical Immunolog. 2012;142:176-193. Impact factor- 3,932
Otylia Kowal-Bielecka1*, Jerome Avouac2*, David Pittrow3, Doerte Huscher4, Frank Behrens5, Christopher P Denton6, Ivan Foeldvari7, Marc Humbert8, Marco Matucci-Cerinic9 Peter Nash10, Christian F. Opitz11, Lewis J Rubin12, James R. Seibold13, Vibeke Strand14, Daniel E Furst15*, Oliver Distler16*, for the EPOSS group. Analysis of the validation status of the quality of life and functional disability measures in scleroderma-related pulmonary arterial hypertension. Results of a systematic literature analysis by the EPOSS (Expert Panel on Outcomes Measures in PAH related to Systemic Sclerosis) group. J Rheumatol 2011,38: 2419-27. Impact factor- 3,551
Heiligenhaus, A, Michels, H.Schumacher, C.Kopp, I.Neudorf, U.Niehues, T.Baus, H.Becker, M.Bertram, B.Dannecker, G.Deuter, C.Foeldvari, I.Frosch, M.Ganser, G.Gaubitz, M.Gerdes, G.Horneff, G.Illhardt, A.Mackensen, F.Minden, K.Pleyer, U.Schneider, M.Wagner, N.Zierhut, M. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2011, 32:1121-33. Impact factor- 3,932
I.Foeldvari , A.Tyndall A, F. Zulian , U. Muller-Lander, L. Czirjak, O. Kowal-Bielecka, D. Farge Bancel, M. Matucci-Cerinic on behalf of the members of EUSTAR. ( Co-Authors E.) Juvenile and young adult onset systemic sclerosis share the same organ involvement in adulthood: Data from the EUSTAR database.. Rheumatology 2012 2012,51:832-7. Impact factor- 4,171
Minden K, Niewerth M, Zink A1, Seipelt E, Foeldvari I, Girschick H, Horneff G. Long-term outcome of patients with juvenile idiopathic arthritis (JIA) treated with Etanercept, results of the biologic register JuMBO. Rheumatology 2012, epub March 24.- Impact factor- 4,171
Horneff G, Foeldvari I, Ganser G, Haas JP, Hospach A, Huppertz I. 10 Jahre Erfahrung im deutschen JIA Etanercept Register: Lehren aus wechselnden Patientenpopulationen. Arthritis +rheuma 2011;31:334-342- Impact factor- NN
Heiligenhaus A*, Foeldvari I*, Smith JR, Saurenmann RK, Bodaghi B, de Boer J, Edelsten C, Graham E, Jordi A, Kotaniemi K, Mackensen F, Minden K, Nielsen S, Rabinovich CE, Ramanan AV, Strand V.* AH and IF contributed equally and share first authorship of this manuscript. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: recommendations from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) Arthritis Care and Research 2012, 64:1349-1356.- Impact factor- 4,749
Klein, A, Kaul, I., Foeldvari, I., Ganser, G. Andreas, U.Horneff, G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis. An observational study with patients of the German Methotrexate Registry. Arthritis Care Res 2012; 64: 1349-1356 – Impact facto – 4,749
Gerd Horneff1, Sigrid Fitter1, Ivan Foeldvari2, Kirsten Minden3, Jasmin Kuemmerle-Deschner4, Nicolay Tzaribacev5, Angelika Thon6, Michael Borte7, Gerd Ganser8, Rolf Trauzeddel9, Hans-Iko Huppertz10. Double blind, Placebo-controlled randomized trial with Adalimumab for Treatment of Juvenile Ankylosing Spondylitis (jAS): significant short term improvement. Arthritis Res Ther. 2012 Oct 24;14(5):R230. [Epub ahead of print] – Impact Factor 4,357
NM Wulffraat and Bas Vastert for the SHARE consortium * :*The SHARE consortium consists of the following partners (alphabetical order): Jordi Anton (Spain), Tadej Avcin (Slovenia), Brigitte Bader-Meunier (France), Michael Beresford (UK), Paul Brogan (UK), Liza McCann (UK), Tamas Constantin (Hungary), Dennis Costello (Eurordis), Jasmin Kummerle Deschner(Germany), Pavla Dolezalova (Czech Republic), Gregor Dueckers (Germany), Ivan Foeldvari (Germany), Helen Foster (UK), Joost Frenkel (the Netherlands), Marco Gattorno (Italy), Marisa Giunta D’Albani (JIA Patient Organization, the Netherlands), Claudia Grave (JIA Patient Organization, Germany), Noortje Groot (the Netherlands), Veronique Hentgen (France), Gerd Horneff (Germany), Sylvia Kamphuis (the Netherlands), Isabelle Kone-Paut (France), Pekka Lahdenne (Finland), Bo Magnussen (Sweden), Alberto Martini (Italy), Kirsten Minden (Germany), JJ vd Net (the Netherlands), Seza Ozen (Turkey), Matthew Peak (UK), Clarissa Pilkington (UK), , Bas Vastert (the Netherlands), Carine Wouters (Belgium), Nico Wulffraat (the Netherlands), Pierre Quartier (France), Angelo Ravelli (Italy), Annet v Royen (the Netherlands), Ingrida Rumba (Latvia), Nicola Ruperto (Italy), Silvia Scala (Italy) and Francesco Zulian (Italy): Time to SHARE. Pediatric Rheumatology 2013 ; 11: 5. Impact Factor: 1,44
Gerd Horneff, Ruben Burgos-Vargas, Tamas Costantin, Ivan Foeldvari, Jelena Vojinovic, Vyacheslav G. Chasnyk, Joke Dehoorne, Violeta Panaviene, Gordana Susic, Valda Stanevica, Katarzyna Kobusinska, Zbigniew Zuber, Bogna Dobrzyniecka, Richard Mouy, Ingrida Rumba, Luciana Breda, Pavla Dolezalova, Chantal Job-deslandre, Nico Wulffraat, Daniel Alvarez, Chuanbo Zang, Joseph Wajdula, Deborah Woodworth, Bonnie Vlahos, Alberto Martini, Nicolino Ruperto for the Paediatric Rheumatology International Trials Organisation (PRINTO). Efficacy and Safety of Open-label Etanercept on Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, and Psoriatic Arthritis: Part 1 (Week 12) of the CLIPPER Study Annals Rheum Dis 2013, accepted . Impact factor- 9.087
Ivan Foeldvari1*, Nikolay Tzaribachev2, Randy Cron3. Update of the results of a multinational survey regarding diagnosis and treatment of the temporomandibulare joint involvement in juvenile idiopathic arthritis- reflection of the day to day practice. Pediatric Rheumatology 2014 12:6. Impact factor- 1,47
Marek Bohm1,2, Maria Isabel Gonzalez Fernandez1, Seza Ozen3, Angela Pistorio4, Pavla Dolezalova2, Paul Brogan5, Giancarlo Barbano6, Claudia Sengler7, Marisa Klein-Gitelman8, Pierre Quartier9, Anders Fasth10, Troels Herlin11, Maria Teresa R. A.Terreri12, Susan Nielsen13, Marion A.J. van Rossum14, Tadej Avcin15, Esteban RodolfoCastell16, Ivan Foeldvari17, Dirk Foell18, Anuela Kondi19, Isabelle Koné-Paut20, Rolf-Michael Kuester21, Hartmut Michels22, Nico Wulffraat23, Halima Ben Amer24, ClaraMalattia 25, Alberto Martini1,25, Nicolino Ruperto1, for the Paediatric Rheumatology International Trials Organisation (PRINTO). Clinical feutures of childhood granulomatosis with polyangiitis ( Wegener Granulomatosus). Pediatric Rheumatology Online Journal 2014, 12:18 . Impact factor- 1,47
Schmeling H, MD1; Minden K, MD2; Foeldvari I, MD3; Ganser G, MD4; Hospach T, MD5; Horneff G, MD6 Efficacy and safety of Adalimumab as first and second used biologic agent in juvenile idiopathic arthritis – the German Biologics JIA Registry (BiKeR). Arthritis and Rheumatology 2014 accepted. Impact factor- 7,477
LN Moorthy1, Roy E1, MGE Peterson2, AL Hassett3, Susa Benseler, TJA Lehman2 and the members of our collaborative group….Ivan Foeldvari.. .4 . CONCISE REPORT Quality of life measure in rare systemic inflammatory pediatric rheumatic diseases and its translation to different languages – International effort. Pediatric Rheumatology online Journal 2014, 12 :49 (25 November 2014).
Gerd Horneff 1, K. Minden 2, I Foeldvari3, N Onken4, D. Windschall5, A. Hospach6, G. Ganser7, J. Klotsche8, I. Becker9 . Aktuelles aus dem BIKER-Register. Zeitschrift für Rheumatologie 2014, 73:897-906.
Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Huppertz HI, Deslandre CJ, Minden K, Punaro M, Block AJ, Giannini EH, Martini A for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO Long-term safety, efficacy, and quality of life with intravenous abatacept in juvenile idiopathic arthritis: up to 7 years of treatment. Arthritis Rheumatol 2015; [Epub ahead of print]
Ivan Foeldvari, Ingrid Becker, Gerd Horneff. Methotrexat seems to be protective to develop uveitis as an adverse event. Results from the German Biologics in Pediatric Rheumatology (BIKER) –Registry. Arthritis Care and Research e pub 2015 may 18.
Gerd Horneff, MD1, Ivan Foeldvari, MD2, Kirsten Minden, MD3, Ralf Trauzeddel, MD4, Jasmin B. Kümmerle-Deschner, MD5, Klaus Tenbrock, MD6, Gerd Ganser, MD7, H. Iko Huppertz, MD8 . Efficacy and Safety of Etanercept in Patients With Enthesitis-related Arthritis Juvenile Idiopathic Arthritis: Results from a Phase 3 Randomised Double-Blind Study. Arthritis Rheumatol 2015 epub
Ingegnoli Francesca1,2 , Boracchi Patrizia1,3 , Gualtierotti Roberta2 , Cutolo Maurizio4,Foeldvari Ivan5, on behalf of the EUSTAR co-authors. Patients with juvenile and adult-onset systemic sclerosis have similar nailfold capillaroscopy patterns in adulthood: A EUSTAR case-contol study. Accepted Microvascular Research 2015
Simon Tarp1, Gil Amarilyo2, Ivan Foeldvari3 N. Cohen2, T. D. Pope4, J. M. Woo4, Robin Christensen1, Daniel E. Furst4. Efficacy and safety of biologic agents for systemic juvenile idiopathic arthritis: A systematic review and meta-analysis of randomized trials. E pub in Rheumatology 2015 , nov 30th.
amas Constantin,1 Ivan Foeldvari,2 Jelena Vojinovic,3 Gerd Horneff,4 Ruben Burgos-Vargas,5 Irina Nikishina,6 Jonathan D Akikusa,7 Tadej Avcin,8 Jeffrey Chaitow,9 Elena Koskova,10 Bernard R Lauwerys,11 Inmaculada Calvo Penades,12 Berit Flato,13 Maria Luz Gamir,14 Hans-Iko Huppertz,15 Juan Jose Jaller Raad,16 Katerina Jarosova,17 Jordi Anton Lopez,18 Marie Macku,19 William J Otero Escalante,20 Lidia Rutkowska Sak,21 Ralf Trauzeddel,22 Patricia J Velez-Sanchez,23 Carine Wouters,24 Joseph Wajdula,25 Chuanbo Zang,25 Jack Bukowski,25 Deborah Woodworth,25 Bonnie Vlahos,25 Alberto Martini,26, 27 Nicolino Ruperto27 for the Paediatric Rheumatology International Trials Organisation (PRINTO). Two-year efficacy and safety of etanercept in paediatric patients with extended oligoarthritis, enthesitis-related arthritis or psoriatic arthritis. Journal of Rheumatology accepted 2015
Smith, Vanessa; Beeckman, Sam; Herrick, Ariane; Decuman, Saskia; Deschepper, Ellen; De Keyser, Filip; Distler, Oliver; Foeldvari, Ivan; Ingegnoli, Francesca; Müller-Ladner, Ulf; Riccieri, Valeria; Riemekasten, Gabriela; Sulli, Alberto; Voskuyl, Alexandre; Cutolo, Maurizio. An EULAR study group pilot study on reliability of “simple” capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology 2015, accepted
Daniel J. Lovell, MD, MPH,1 Nicolino Ruperto, MD, MPH,2 Richard Mouy, MD,3 Eliana Paz, MD,4 Nadina Rubio-Pérez, MD,5 Clovis A. Silva, MD, PhD,6 Carlos Abud-Mendoza, MD,7 Ruben Burgos-Vargas, MD,8 Valeria Gerloni, MD,9 Jose A. Melo-Gomes, MD,10 Claudia Saad-Magalhaes, MD, PhD,11 J. Chavez-Corrales, MD,12 Christian Huemer, MD,13 Alan Kivitz, MD, CPI,14 Fransico J. Blanco, MD,15 Ivan Foeldvari, MD,16 Michael Hofer, MD,17 Hans-Iko Huppertz, MD,18 Chantal Job Deslandre, MD,19 Kirsten Minden, MD,20 Marilynn Punaro, MD, 21 Alan J. Block, PhD,22 Edward H. Giannini, MSc, DrPH,1 and Alberto Martini, MD,2,23 for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO. Long-term safety, efficacy, and quality of life with intravenous abatacept in JIA: Up to 7 years of treatment. Accepted in Arthritis and Rheumatism 2015
Simon Tarp1, Gil Amarilyo2, Ivan Foeldvari3 N. Cohen2, T. D. Pope4, J. M. Woo4, Robin Christensen1, Daniel E. Furst4. Efficacy and safety of biologic agents for systemic juvenile idiopathic arthritis: A systematic review and meta-analysis of randomized trials. Rheumatology 2016, 55: 669-679.
Tamas Constantin,1 Ivan Foeldvari,2 Jelena Vojinovic,3 Gerd Horneff,4 Ruben Burgos-Vargas,5 Irina Nikishina,6 Jonathan D Akikusa,7 Tadej Avcin,8 Jeffrey Chaitow,9 Elena Koskova,10 Bernard R Lauwerys,11 Inmaculada Calvo Penades,12 Berit Flato,13 Maria Luz Gamir,14 Hans-Iko Huppertz,15 Juan Jose Jaller Raad,16 Katerina Jarosova,17 Jordi Anton Lopez,18 Marie Macku,19 William J Otero Escalante,20 Lidia Rutkowska Sak,21 Ralf Trauzeddel,22 Patricia J Velez-Sanchez,23 Carine Wouters,24 Joseph Wajdula,25 Chuanbo Zang,25 Jack Bukowski,25 Deborah Woodworth,25 Bonnie Vlahos,25 Alberto Martini,26, 27 Nicolino Ruperto27 for the Paediatric Rheumatology International Trials Organisation (PRINTO). Two-year efficacy and safety of etanercept in paediatric patients with extended oligoarthritis, enthesitis-related arthritis or psoriatic arthritis. Journal of Rheumatology 2016, 43: 816-824.
Smith, Vanessa; Beeckman, Sam; Herrick, Ariane; Decuman, Saskia; Deschepper, Ellen; De Keyser, Filip; Distler, Oliver; Foeldvari, Ivan; Ingegnoli, Francesca; Müller-Ladner, Ulf; Riccieri, Valeria; Riemekasten, Gabriela; Sulli, Alberto; Voskuyl, Alexandre; Cutolo, Maurizio. An EULAR study group pilot study on reliability of “simple” capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology 2016, 55:883-890.
Clare E. Pain, Tamás Constantin, Natasa Toplak, Monika Moll, Christof Iking-Konert: Daniella P. Piotto, Nuray Aktay Ayaz, Dana Nemcova, Peter H. Hoeger; Maurizio Cutolo, Smith, Ivan Foeldvari. Raynaud´s Syndoreme in children: Systemiatic review and development of recommendations for assessment and monitoring. Clinical Expermimental Rheumatology 2016 , e pub 27.July 2016
Horneff G, Klein A, Oommen P, Hospach A, Foeldvari I, Feddersen I, Minden K. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry- Clinical Experimantel Rheumatology 2016, 34:1113-1120.
Seza Ozen, Jasmin B Kuemmerle-Deschner, Isabelle Kone-Paut, Veronique Hentgen, Pierre Quartie, Tilmann Kallinich, Rolando Cimaz, Luca Cantarini, Steve Spalding, Andrew Zeft, Avi Livneh, Ivan Foeldvari, Joost Frenkel, Ahmet Gul, Sinisa Savic, Jeffrey, Dony Patel, Nina Marinsek, Ravi Degun, Kathleen G Lomax, Helen J Lachmann. International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD/HIDS. Arthrits Care and Therapy 2016, in print
Otylia Kowal-Bielecka1, Jaap Fransen2, Jerome Avouac3, Mike Becker4, Agnieszka Kulak1, Yannick Allanore3, Oliver Distler5, Philip Clements6, Maurizio Cutolo7, Laszlo Czirjak8, Nemania Damjanov9, Francesco del Galdo10, Chris Denton11, Joerg Distler12, Ivan Foeldvari13, Kim Fligelstone14, Marc Frerix15, Daniel Furst6, Serena Guiducci16, Nicolas Hunzelmann17, Dinesh Khanna18, Marco Matucci-Cerinic16, Ariane Herrick19, Frank van den Hoogen2, Jaap van Laar20, Gabriela Riemekasten21, Richard Silver22, Vanessa Smith23, Alberto Sulli7, Ingo Tarner15, Alan Tyndall24, Joep Welling25, Frederic Wigley26, Gabriele Valentini27, Ulrich Walker24, Francesco Zulian28, Ulf Müller-Ladner15 on behalf of EUSTAR. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2016. Epub Nov 9th 2016.
Gil Amarilyo, MD¹*, Simon Tarp, MSc²*, Ivan Foeldvari, MD³, Neta Cohen, MD¹, Tracy Danielle Pope, BS⁴, Jennifer Mei Ping Woo, MPH⁴, Robin Christensen, MSc, PhD², Daniel Eric Furst, MD⁴. Biologic agents in polyarticular JIA: a meta-analysis of randomized controlled trials. Semin Arthrits Rheum 2016, 46:312-8.
Dinesh Khanna¹, Daniel E. Furst², Philip J. Clements², Yannick Allanore³, Lazlo Czirjak⁴, Oliver Distler⁵, Ivan Foeldvari⁶ ,Masataka Kuwana⁷, Marco Mattucci-Cerinic⁸, Maureen Mayes⁹, Thomas Medsger¹⁰, Jr, Peter Merkel¹¹, James Seibold¹², Virginia Steen¹³, Christopher P. Denton¹⁴ on behalf of the SCTC and the WSF. Use and standardization of the modified Rodnan skin score in clinical trials of systemic sclerosis. Journal of Scleroderma and Related Disorders 2017, page 000
Weiß A¹, Listing J¹, Minden K^1,2, Foeldvari I³, Sieper J², Rudwaleit M^4. Course of patients with juvenile Spondyloarthritis during 4 years of observation, juvenile part of GESPIC.RMD open Journal. 2016-000366.R2. accepted 2017
Hermine I. Brunner*, Nicolino Ruperto*, Nikolay Tzaribachev, Gerd Horneff, Vyacheslav Chasnyk, Violeta Panaviene, Carlos AbudMendoza, Andreas Reiff, Ekaterina Aleksxeeva, Nadina Rubio-Pérez, Vladimir Keltsev, Daniel J. Kingsbury, Maria del Rocio Maldonado, Irina Nikishina, Earl D. Silverman, Rik Joos, Elzbieta Smolewska, Marcia Bandeira, Kirsten Minden, Annet van Royen-Kerkhof, Wolfgang Emminger, Ivan Foeldvari, Bernard R. Lauwerys, Flavio Sztajnbok, Keith E. Gilmer, Jocelyn H. Leu, Lilianne Kim, Sarah L. Lamberth, Matthew J. Loza, Daniel J. Lovell, Alberto Martini, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). *Contributed equally to the publication. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis despite methotrexate therapy: Results of a multicenter, double-bind, randomized-withdrawal trial. Annals of Rheumatic Diseases on line 16th of May 2017
Johnson, Sindhu; Soowamber, Medha;Fransen, Jaap; Khanna, Dinesh; van den Hoogen, Frank; Baron, Murray; Matucci Cerinic, Marco; Denton, Christopher P. ; Medsger,Thomas; Carreira, Patricia; Riemekasten, Gabriela; Distler, Joerg; Gabrielli, Armando; Steen, Virginia; Chung, Lorinda; Silver, Richard;Varga, John; Müller-Ladner, Ulf; Vonk, Madelon; Walker, Ulrich; Wollheim, Frank; Herrick, Ariane; Furst, Daniel; Czirják, László; Kowal-Bielecka, Otylia ; Del Galdo, Francesco; Cutolo, Maurizio; Hunzelmann, Nicolas; Murray, Charles D.; Foeldvari, Ivan; Mouthon, Luc;Damjanov, Nemanja; Kahaleh, Bashar; Frech, Tracy; Assassi, Shervin; Saketkoo, Lesley Ann; Pope, Janet. There is a need for new systemic sclerosis subset criteria.A content analytic approach. Accpepted Scandinavian Journal of Rheumatology
Dirk Holzinger¹, Dirk Foell¹, Gerd Horneff², Ivan Foeldvari³, Nikolay Tzaribachev⁴, Catrin Tzaribachev⁴, Kirsten Minden⁵, Tilmann Kallinich⁵, Gerd Ganser⁶, Lucia Clara⁶, Johannes-Peter Haas⁷, Boris Hügle⁷, Hans-Iko Huppertz⁸, Frank Weller⁸, Alessandro Consolaro^9,10, Francesca Bovis⁹, Nicolino Ruperto⁹for the Paediatric Rheumatology International Trials Organisation (PRINTO). The German version of the Juvenile Arthritis Mulitdimensional assessment report (JAMAR). Accepted Rheumatology International 2017.
Francesca Ingegnoli¹, Nicola Ughi¹, Graham Dinsdale², Annalisa Orenti³, Patrizia Boracchi³, Vanessa Smith⁴, Yannick Allanore⁵, Ivan Foeldvari⁶, Alberto Sulli⁷, Maurizio Cutolo⁷, Ariane L Herrick^2,8, on behalf of the EULAR Study Group on Microcirculation in Rheumatic Diseases. An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud’s phEnomenon (SUNSHINE survey). Accepted Rheumatology International 2017.
Ivan Foeldvari, Jordi Anton, Marc Friswell, Blanca Bica, Jaime Innocencio, Rebecca Nicolai, Nicola Helmus. Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients. Accepted to Journal of Scleroderma an associated conditions (2017)
Gerd Horneff; Ariane Klein; Gerd Ganser; Michaela Sailer-Hoeck; Annette Guenther; Ivan Foeldvari; Frank Weller-Heinemann. Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): Results of the working group Polyarticular juvenile idiopathic arthritis. Pediatric Rheumatology 2017, 15:78.
Horneff G1 Schulz AC1, Klotsche J3, Hospach A2, Minden K3, Foeldvari I4, Trauzeddel R5, Ganser G6, Weller-Heinemann F7, Haas JP8. Experience with Etanercept, Tocilizumab and Interleukin-1 inhibitors in systemic onset Juvenile Idiopathic Arthritis patients from the BIKER registry. ARRT-D-17-00231R2 in Arthritis Research & Therapy.
Shenoi S, Horneff G, Cidon M, Ramanan A, Kimura Y, Quartier P, Foeldvari I,… Wulfraat N. The Burden of Systemic Juvenile Idiopathic Arthritis (SJIA) for Patients and Caregivers: An International Survey and Retrospective Chart Review- Clinical and Experimental Rheumatology accepted 2017.
Nicolino Ruperto,1 Hermine I Brunner,2 Zbigniew Zuber,3 Nikolay Tzaribachev,4 Daniel J Kingsbury,5 Ivan Foeldvari,6 Gerd Horneff,7 Elena Koskova,8 Elzbieta Smolewska,9 Richard K Vehe,10 Anasuya Hazra,11 Rong Wang,12 Charles A Mebus,12 Christine Alvey,12 Manisha Lamba,12 Sriram Krishnaswami,12 Thomas C Stock,11 Min Wang,11 Ricardo Suehiro,11 Alberto Martini1 Daniel J Lovell,2 for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a Phase 1, open-label, multicenter study. Pediatric Rheumatology 2017,15:86
Claas H. Hinze1, Dirk Holzinger1, Elke Lainka2, Johannes-Peter Haas3, Fabian Speth3, Tilmann Kallinich4, Nikolaus Rieber5, Markus Hufnagel6, Annette Jansson7, Christian Hedrich8, Hanna Winowski9, Thomas Berger10, Ivan Foeldvari11, Gerd Ganser9, Helmut Wittkowski1, Gerd Horneff12 and Dirk Foell1 . Practice and Consensus-Based Strategies in Diagnosing and Managing Systemic Juvenile Idiopathic Arthritis in Germany. Pediatric Rheumatology 2018 , 16:7 (PROJ-D-17-00136R1).Timothy Beukelman, Fenglong Xie, Ivan Foeldvari. Assessing the Prevalence of Juvenile Systemic Sclerosis in Childhood Using Administrative Claims Data from the United States. Acccepted 15 th of February 2018 Journal of Scleroderma and Related Disorders
Hermine I Brunner,1 Daniel J Lovell,1 Alberto Martini,2 Nikolay Tzaribachev,3 Gabriel Vega-Cornejo,4 Ingrid Louw,5 Alberto Berman,6 Inmaculada Calvo Penadés,7 Francisco Ávila-Zapata,8 Ruben Cuttica,9 Gerd Horneff,10 Jordi Antón,11 Ivan Foeldvari,12 Vladimir Keltsev,13 Daniel J Kingsbury,14 Diego Oscar Viola,15 Rik Joos,16 Maria Teresa Apaz,17 Bernard Lauwerys,18 Carine Wouters,19 Mahmood Ally,20 John Bohnsack,21 Johannes Breedt,22 Michel Fischbach,23 Thomas Lutz,24 Kirsten Minden,25 Tatiana Miraval,26 Maria Elena Rama,27 Nadina Rubio Perez,28 Riana van Zyl,29 Xiaohui Li,30 Marleen Nys,31 Robert Wong,30 Subhashis Banerjee,30 Nicolino Ruperto2 for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous abatacept in patients with polyarticular juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis and Rheumatology accepted 24.02.2018
Tamás Constantin,1 Ivan Foeldvari,2 Jordi Anton,3 Joke de Boer,4 Severine Czitrom-Guillaume,5 Clive Edelsten,6 Raz Gepstein,7 Arnd Heiligenhaus,8,9 Clarissa Pilkington,10 Gabriele Simonini,11 Yosef Uziel,12 Bas Vastert,13 Nico Wulffraat,13 Anne-Mieke Haasnoot,4 Karoline Walscheid,8 Annamária Pálinkás,14 Reshma Pattani,15 Zoltán Györgyi,16 Richárd Kozma,17 Victor Boom,13 Andrea Ponyi,1 Angelo Ravelli,18 Athimalaipet V Ramanan19. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis. Ann Rheum Dis 2018, 77:1107-1117.
Edoardo Marrani, Ivan Foeldvari, Jord Anton Lopez, Rolando Cimaz, Gabriele Simonini. Comparing (P)UVA with MTX protocol in childhood Localized Scleroderma: evidence from systematic review and meta-analysis approach. Seminars in Arthritis and Rheumatism accepted 13.03.18
Tamás Constantin, Ivan Foeldvari, Clare E Pain, Kathryn S. Torok, Annamária Pálinkás, Peter Höger, Monika Moll, Dana Nemkova, Lisa Weibel, Melinda Laczkovszki, Philip Clements. Development of Minimum Standards of Care for Juvenile Localized Scleroderma. European Journal of Pediatrics: 2018, 177,961-977.
Sandra Schenck1, Joachim Rosenbauer2,3, Martina Niewerth1, Jens Klotsche1,4, Kirsten Minden1,5, Tobias Schwarz6, Ivan Foeldvari7, Gerd Horneff8, Frank Weller-Heinemann9, Reinhard W. Holl10, Angelika Thon11 Comorbidity of type 1 diabetes mellitus in patients with juvenile idiopathic arthritis. Journal of Pediatrics. 2018,192:196-203.
Suzanne C. Li, MD PhD1 , Xiaohu Li, PhD2 ,Elena Pope, MD3 ,Katie Stewart, MD4 ,Gloria C. Higgins, MD PhD5 ,C. Egla Rabinovich, MD MPH6 ,Kathleen M. O’Neil, MD7 ,Kathleen A. Haines, MD1 ,Ronald M. Laxer, MD3 ,Marilynn Punaro, MD4 ,Heidi Jacobe, MD8 ,Tracy Andrews, MA10 ,Knut Wittkowski, PhD9 ,Themba Nyirenda, PhD10 ,Ivan Foeldvari, MD11 , Kathryn S. Torok, MD12 . New Features for Measuring Disease Activity in Juvenile Localized Scleroderma. Journal of Rheumatology epub September 15 2018
Murray Baron, MD1, Bashar Kahaleh, MD2, Elena J. Bernstein, MD, MSc3, Lorinda Chung, MD, MS4, Philip J. Clements, MD MPH5, Christopher Denton, PhD, FRCP6, Robyn T. Domsic, MD MPH7, Nava Ferdowsi, MD8, Ivan Foeldvari, MD9, Tracy Frech, M.D., M.S.10, Jessica K. Gordon, MSc MD11, Marie Hudson, MD1, Sindhu R. Johnson, MD PhD12, Dinesh Khanna, M.D., M.S.13, Zsuzsannah McMahan, M.D., M.H.S.14, Peter A. Merkel, MD MPH15,SonaliNarain, M.B.B.S., M.P.H.16, MandanaNikpourMBBS FRACP PhD8, John D. Pauling, MD PhD17 , Laura Ross, MD PhD8, Antonia Maria Valenzuela Vergara, MD, MS4, Alexandra Vacca, M.D.18 An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. Journal of Scleroderma and Related Disorders- accepted 28.05.2018
I. Foeldvari 1, J. Klotsche2, K. Torok O. Kasapcopur3, A. Adrovic3, V. Stanevicha4, M.T. Terreri 5, E. Alexeeva6, M.M. Katsicas 7, R. Cimaz 8, M. Kostik 9, T. Lehman10, W. A. Sifuentes-Giraldo 11, V. Smith12, F. Sztajnbok 13, T. Avcin 14, M. Jose Santos 15, M. Moll 16, D. Nemcova 17, C. Battagliotti18, D. Eleftheriou 19, H. Liora20, M. Janarthanan 21, T. Kallinich 22, J. Lopez23, K.Minden 22, S. Nielsen 24, 25, Y.Uziel 26, N. Helmus 1. CHARACTERISTICS OF THE FIRST 80 PATIENTS AT TIMEPOINT OF FIRST ASSESSMENT INCLUDED IN THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILESCLERODERMA.COM. Journal of Scleroderma and Related Disorders 2018, I-13. „https://doi.org/10.1177/2397198318790494
Kirsten Minden, MD1,2, Gerd Horneff, MD3, Martina Niewerth, MPH1, Eva Seipelt, MD4, Peer Aries, MD5, Martin Aringer, MD6, Erich Bärlin, MD7, Christina Baumann, MD8, Ivan Foeldvari, MD9, Johannes-Peter Haas, MD10, Ariane Klein, MD3, Frank K Striesow, MD11, Klaus Tenbrock, MD12, Angela Zink, PhD 1,2, Jens Klotsche, PhD1,2 The time of DMARD start in Juvenile Idiopathic Arthritis determines the outlook for a drug-free remission in young adulthood. Arthritis Care and Research accepted 17th of July 2018
Timothy Beukelman, Fenglong Xie, Ivan Foeldvari. Assessing the Prevalence of localized scleroderma in childhood using Administrative Claims Data from the United States. Journal of Scleroderma and Related Disorders 2018, I-2, DOI: 10.1177/2397198318798588.
P. Dolezalova1, J. Anton2, T. Avcin3, M. Beresford 4, P. A. Brogan5, T. Constantin6, Y. Egert7, I. Foeldvari8, H.E. Foster9, V. Hentgen10, I. Kone-Paut11, J. Kummerle-Deschner12, P. Lahdenne13, B. Magnusson14, A. Martini15, L. McCann4, K. Minden16, S. Ozen17, C. Schoemaker18, P. Quartier19, A. Ravelli15, I. Rumba20, N. Ruperto15, S. Vastert18, C. Wouters21, F. Zulian22, and N.M. Wulffraat18 for the SHARE consortium The European network for care of children with Paediatric Rheumatic Diseases: care across borders. Rheumatology accepted 24.11.18
Heiligenhaus A#1, Minden K2, Tappeiner C1, Baus H5, Bertram B3, Deuter C1, Foeldvari I2, Föll D2, Frosch M2, Ganser G2, Gaubitz M4, Günther A2, Heinz C1, Horneff G2, Huemer C2, Kopp I6, Lommatzsch C1, Lutz T2, Michels H2, Neß T1, Neudorf U2, Pleyer U1, Schneider M4, Schulze-Koops H4, Thurau S1, Zierhut M1, Lehmann HW2. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism accepted 29.11.18
Joost Swart*1, Gabriella Giancane*2, Gerd Horneff3, Bo Magnusson4, Michael Hofer5, Еkaterina Alexeeva6, Violeta Panaviene7, Pierre Quartier8, Jordi Anton9, Susan Nielsen10, Fabrizio De Benedetti11, Sylvia Kamphuis12, Valda Staņēviča13, Maria Trachana14, Constantin Ailioaie15, Elena Tsitsami16, Ariane Klein3, Kirsten Minden17, Ivan Foeldvari18, Johannes Peter Haas19, Jens Klotsche17, Alessandro Consolaro20, Francesca Bovis2, Francesca Bagnasco2, Angela Pistorio21, Alberto Martini22, Nico Wulffraat1, Nicolino Ruperto2 for the Paediatric Rheumatology International Trials Organisation (PRINTO), BIKER and the board of the Swedish Registry. PHARMACOVIGILANCE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH BIOLOGIC OR SYNTHETIC DRUGS: COMBINED DATA OF MORE THAN 15,000 PATIENTS FROM PHARMACHILD AND NATIONAL REGISTRIES. in Arthritis Research and Therapy 2018; 20:285
Francesco Zulian1, Roberta Culpo1, Francesca Sperotto1, Jordi Anton2, Tadej Avcin3, Eileen Baildam4, Christina Boros5, Jeffrey Chaitow6, Tamas Constantin7, Ozgur Kasapcopur8, Sheila Knupp Feitosa de Oliveira9, Clarissa Pilkington10, Ricardo Russo11, Natasa Toplak3, Annet v Royen12, Claudia Saad Magalhaes13, Sebastiaan Vastert14, Nico Wulffraat14, Ivan Foeldvari15
CONSENSUS-BASED RECOMMENDATIONS FOR THE MANAGEMENT OF JUVENILE LOCALIZED SCLERODERMA. Ann Rheum Dis . 2019,78:1019-1024.
Klein, Ariane; Becker, Ingrid; Minden, Kirsten; Foeldvari, Ivan; Haas, Johannes-Peter; Horneff, Gerd. dalimumab versus Adalimumab and MTX for the treatment of juvenile idiopathic arthritis. Long-Term data from the German BiKeR registry. Submitted to Rheumatology. Scan J Rheumatol 2019, 48:95-104.
Ivan Foeldvari1, Tamàs Constantin2, Jelena Vojinovic3, 4, Gerd Horneff5, 6, Vyacheslav Chasnyk7, Joke Dehoorne8, Violeta Panaviene9, 10, Gordana Sušiæ11, Valda Stanevicha12, Katarzyna Kobusinska13, Zbigniew Zuber14, Bogna Dobrzyniecka15, Irina Nikishina16, Brigitte Bader-Meunier17, Luciana Breda18, Pavla Doležalová19, Chantal Job Deslandre20, Ingrida Rumba-Rozenfelde21, Nico Wulffraat22, Ronald D. Pedersen,23 Jack Bukowski,23 Bonnie Vlahos,23 Alberto Martini24 and Nicolino Ruperto25 for the Paediatric Rheumatology International Trials Organisation (PRINTO) Etanercept Treatment for Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: Six-Year Efficacy And Safety Data From An Open-Label Trial. Arthritis Research and Therapy accepted 08.05.19
V. Smith1*, A. Vanhaecke2*, AL. Herrick3, O. Distler4, MG Guerra5, CP. Denton6, R. De Angelis7, E. Deschepper8, I. Foeldvari9, E. Hachulla10, F. Ingegnoli11, U. Müller-Ladner12, V. Riccieri13, A. Sulli14, JM. van Laar15, M. Vonk16, M. Cutolo17 for the EULAR Study Group on Microcirculation in Rheumatic Diseases. Fast track algorithm: How to differentiate a scleroderma pattern from a non-scleroderma pattern. Auto-Immunity reviews. 2019 Sep 11. Doi: 10.1016/j.autrev.2019.102394 Epub- PMID 31520797
Mastrangelo G, Foeldvari I, Anton-Lopez J, Simonini G. Reviewing Outcome Measures in Juvenile Idiopathic Arthritis associated-uveitis. Do we need a consensus?. Pediatric Rheumatology 2019, 17:40
Ivan Foeldvari; Jens Klotsche; Gabriele Simonini; Clive Edelsten; Sheila T. Angeles-Han; Regitze Bangsgaard; Joke de Boer; Gabriele Brumm; Rosa Bou Torrent; Tamas Constantin; Cinzia DeLibero; Jesus Diaz; Valeria Maria Gerloni; Margarida Guedes; Arnd Heiligenhaus; Kaisu Kotaniemi; Sanna Leinonen; Kirsten Minden; Vasco Miranda; Elisabetta Miserocchi; Susan Nielsen; Martina Niewerth; Irene Pontikaki; Carmen Garcia de Vicuna; Carla Zilhao; Steven Yeh; Jordi Anton. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). Pediatric Rheumatology 2019,17:66. doi.org/10.1186/s12969-019-0345-2
Gabriele Valentini1, Dörte Huscher2, Antonella Riccardi1, Serena Fasano1, Rosaria Irace1, Valentina Messiniti1, Marco Matucci Cerinic3, Serena Guiducci3, Oliver Distler4, Britta Maurer4, Jérome Avouac5, Ingo H Tarner6, Marc Frerix6, Gabriela Riemekasten7, Elise Siegert8, László Czirják9, Veronika Lóránd9, Christopher P Denton10, Svetlana Nihtyanova10, Ulrich A Walker11, Veronika K Jaeger11, Francesco Del Galdo12, Giuseppina Abignano12, Lidia P Ananieva13, Ana Maria Gheorghiu14, Jörg Henes15,Tim Schmeiser16, Alessandra Vacca17, Sergey Moiseev18, Ivan Foeldvari19, Armando Gabrielli20, Brigitte Krummel-Lorenz21, Simona Rednic22, Yannick Allanore5, Ulf Müller Ladner6. PRIMARY MYOCARDIAL DISEASE IN SYSTEMIC SCLEROSIS: Preventative role of vasodilator therapy as assessed by the DeSScipher inception cohort study. Ann Rheum Dis (http:// dx. doi. org/ 10. 1136annrheumdis- 2019- 215145
H.I. Brunner1, N Ruperto2, K Nanda3, M Toth4, I Foeldvari5, J Bohnsack6, D Milojevic7, C Rabinovich8, D Kingsbury9, K Marzan10, P Quartier11, K Minden12, E Chalom1, G Horneff13, RM Kuester14, J Dare15, M Bereswill16, J Kalabic16, H Kupper16D Lovell1, A Martini2 Safety and Effectiveness of Adalimumab in Patients with Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA): 7-Year Interim Results from the STRIVE Registry. Arthritis Care and Therapy. DOI: 10.1002/acr.24044. 14.08.19
A. Klein1, 2, I Becker3, K. Minden4 , A. Hospach5 , G. Ganser6, I. Foeldvari7, M.Borte8, F. Weller-Heinemann9, F. Dressler, G10., J. Kuemmerle-Deschner11 , PT Oommen12 , D. Foell13, C. Rietschel14, Horneff1, 2 Biologic therapies in polyarticular juvenile idiopathic arthritis. Comparison of long-term safety. Data from the German BIKER registry. ACR Open. Accepted 17.09.19
T.Scheer, J. Klotsche, C.Len, I. Foeldvari. Validation and adaptation of a screening tool in German language to identify patients at risk for juvenile idiopathic arthritis. Rheumatol International accepted 15.10.19. https://doi.org/10.1007/s00296-019-04465-8
Lina von Schuckmann, Anna Suling, Bärbel Kahl-Niek, Ivan Foeldvari. Juvenile Idiopathic Arthritis and the Temporomandibular Joint: Prevalence, Risk Factors and Diagnostic Tools. Scandinavian Journal of Rheumatology. 2020, 49: 271-280. 10.1080/03009742.2020.1720282
Vanessa Smith1*, Ariane L. Herrick2*, Francesca Ingegnoli3*, Rossella De Angelis4, Christopher P. Denton5, Oliver Distler6, Ivan Foeldvari7, Tracy Frech8, Marwin Gutierrez9, Genevieve Gyger10, Eric Hachulla11, Roger Hesselstrand12, Cristiane Kayser13, Karin Melsens14, Ulf Müller-Ladner15, Carmen Pizzorni16, Mislav Radic17, Valeria Riccieri18, Marcus Snow19, Wendy Stevens20, Alberto Sulli21, Jacob M. van Laar22, Madelon C. Vonk23, Amber Vanhaecke24, Maurizio Cutolo25 and the EULAR Study Group on Microcirculation in Rheumatic Diseases and the Scleroderma Clinical Trials Consortium group on capillaroscopy. STANDARDISATION OF NAILFOLD CAPILLAROSCOPY FOR THE ASSESSMENT OF PATIENTS WITH RAYNAUD’S PHENOMENON AND SYSTEMIC SCLEROSIS. Autoimmune Reviews. 2020, 19, 102458, Doi.org/10.1016/j.autrev.2020.102458
A. Klein. K.Minden, A. Hospach, I.Foeldvari, F.Weller, R. Trauzeddel, H.I.. Huppertz, G. Horneff. Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis. Ann Rheum Disease. 2020, 79:969-974.
Anna-Maria Hoffmann-Vold, Toby M Maher, PhD; Edward E Philpot, MD; Ali Ashrafzadeh, MD; Rafic Barake, MD; Simone Barsotti, MD PhD; Cosimo Bruni, MD; Paolo Carducci, MD; Patricia E Carreira, MD; Ivan Castellví, MD PhD; Francesco Del Galdo, MD PhD; Jörg H Distler, MD; Ivan Foeldvari, MD; Paolo Fraticelli, MD PhD; Peter M George, PhD; Bridget Griffiths, MD; Alfredo Guillén-Del-Castillo, MD; Abdul Monem Hamid, MD; Rudolf Horváth, PhD; Michael Hughes, PhD; Michael Kreuter, MD; Florentine Moazedi-Fuerst, MD; Jacek Olas; Suman Paul, MRCP; Cinzia Rotondo, MD; Manuel Rubio-Rivas, MD PhD; Andrei Seferian, MD MS; Michal Tomčík, MD PhD; Yurdagül Uzunhan, MD PhD; Ulrich A Walker, MD; Ewa Więsik-Szewczyk, PhD; Oliver Distler, MD. Evidence-based consensus statements for the identification and management of interstitial lung disease in systemic sclerosis. The Lancet Rheumatology 2020, 2:e71-83.
A. Klein1,2, J. Klotsche3, B. Hügle4, K. Minden3, A. Hospach5, F Weller-Heinemann6, T. Schwarz7, F. Dressler8, R. Trauzeddel9, M. Hufnagel10, I. Foeldvari11, M.Borte12,.J.Kuemmerle-Deschner13, J. Brunner14, P.T. Oommen15, D. Föll16, K. Tenbrock17, A. Urban18, G. Horneff1 . Long-Term Surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis. Data from the German BIKER registry. Rheumatology. 2020,59:2287-2298.
Seza Ozen, Eldad Ben-Chetrit, Ivan Foeldvari, Gil Amarilyo, Huri Ozdogan, Steven Vanderschueren, Katherine Marzan, Joanne Kahlenberg, Elise Dekker, Fabrizio De Benedetti, Isabelle Kone-Paut. Long-term Safety and Efficacy of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever (crFMF): Results from the Pivotal Phase 3 CLUSTER Trial. Ann Rheum Dis 2020, 79:1362-69.
Ivan Foeldvari15, Roberta Culpo1, Francesca Sperotto1, Jordi Anton2, Tadej Avcin3, Eileen Baildam4, Christina Boros5, Jeffrey Chaitow6, Tamas Constantin7, Ozgur Kasapcopur8, Sheila Knupp Feitosa de Oliveira9, Clarissa Pilkington10, Ricardo Russo11, Natasa Toplak3, Annet v Royen12, Claudia Saad Magalhaes13, Nico Wulffraat14, Francesco Zulian1 and. CONSENSUS-BASED RECOMMENDATIONS FOR THE MANAGEMENT OF JUVENILE SYSTEMIC SCLEROSIS. Rheumatology 2020. doi:10.1093/rheumatology/keaa584
Ivan Foeldvari MD1, Jens Klotsche MD2, Ozgur Kasapcopur MD3, Amra Adrovic MD3, Maria Teresa Terreri MD4, Ana Paula Sakamoto MD4, Valda Stanevicha MD5, Flavio Sztajnbok MD6, Jordi Anton MD7, Brian Feldmann MD8, Ekaterina Alexeeva MD9, Maria Katsicas MD10, Vanessa Smith MD11, Tadej Avcin MD12, Edoardo Marrani MD13, Mikhail Kostik MD14, Thomas Lehman MD15, Walter-Alberto Sifuentes-Giraldo MD16, Natalia Vasquez-Canizares MD17, Simone Appenzeller MD18, Mahesh Janarthanan MD19, Monika Moll MD20, Dana Nemcova MD21, Anjali Patwardhan MD22, Maria Jose Santos MD23, Sujata Sawhney MD24, Dieneke Schonenberg-Meinema MD25, Cristina Battagliotti MD26, Lillemor Berntson MD27, Blanca Bica MD28, Jürgen Brunner MD29, Patricia Costa-Reis MD30, Despina Eleftheriou MD31, Liora Harel MD32, Gerd Horneff MD33, Daniela Kaiser MD34, Tilmann Kallinich MD35, Dragana Lazarevic MD36, Kirsten Minden MD35, Susan Nielsen MD37, Farzana Nuruzzaman MD38, Yosef Uziel MD39, Nicola Helmus1, Kathryn S. Torok MD4 0 Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in expanded international cohort. www.juvenile-scleroderma.com. Arthritis care and Research , 24.03.2021 accepted. DOI: 10.1002/acr.24609
Jean Baer, Jens Klotsche, Ivan Foeldvari. Secukinumab in the treatment for patients with juvenile enthesitis related arthritis nonresponsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index. Clin Exp Rheumatol, 29.03.2021 accepted, 08.06.2021 epub ahead.
Y Desai1, T Jaki1,2, MW Beresford3,4, T Burnett1, D Eleftheriou5, H Jacobe6 , V Leone7, S Li8, P Mozgunov1, A V Ramanan9, KS Torok10, M Anderson11, J Anton12, T Avcin13, J Felton14, I Foeldvari15, B Laguda16, F McErlane17, L Shaw6,9, F Zulian18, CE Pain3 . Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma. AMRC Open Research 2021, 3: 20. doi.org/10.12688/amrcopenres.13008.1
Julien Ross1,2, Ivan Foeldvari3, Sebastian Butscheidt2, Frank Timo Beil2, Ralf Stücker1,2, and Alexander S. Spiro1,2 Does juvenile idiopathic arthritis affect the course of Legg-Calvé-Perthes disease? A matched-control study with a mean follow-up of 8 years. Children, accepted 02.11.2021. Manuscript ID: children-1379279. DOI 10.3390/children8111014
Klotsche J., Klein A. Niewerth M., Hoff P, Windschall D., Foeldvari I, Haas JP,, Horneff. G, Minden K. Re-treatment with etanercept is as effective as the initial first line treatment in patients with juvenile idiopathic arthritis. Arthritis Research & Therapy 2021, 23:118
Alessandra Alongi, MD, PhD1; Gabriella Giancane, MD, PhD2,3; Roberta Naddei, MD3,4; Valentina Natoli, MD3; Francesca Ridella, MD2; Marco Burrone, MD3,5; Silvia Rosina, MD, PhD3; Gaelle Chédeville, MD6; Ekaterina Alexeeva, MD7,8; Gerd Horneff, MD9,10; Ivan Foeldvari, MD11; Giovanni Filocamo, MD12; Tamas Constantin, MD13; Nicolino Ruperto, MD, MPH3; Angelo Ravelli, MD2,8,14*; Alessandro Consolaro, MD, PhD2,3*, for the Pediatric Rheumatology International Trials Organization (PRINTO). Impact of discordance between physician’s global assessment and active joint count on the definition of inactive disease in juvenile idiopathic arthritis. RMD open accepted 02/2022
Foeldvari, Ivan; Maccora, Ilaria; Petrushkin, Harry; Rahman, Najiha; Anton, Jordi; de Boer, Joke; Calzada Hernandez, Joan; Carreras, Elisa; Diaz, Jesus; Edelsten, Clive; Angeles-Han, Sheila; Heiligenhaus, Arnd; Miserocchi, Elisabetta; Nielsen, Susan; Saurenmann, Rotraud; Stübiger, Nicole; Walscheid, Karoline; Furst, Daniel; Simonini, Gabriele. „New and updated recommendations for the treatment of juvenile idiopathic arthritis associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care and Therapy (accepted 10th of May 2022)
S. Johnson, I Foeldvari. Approach to pa0ent assessment: How does pa0ent subsettng help ? Rhematic Disease Clinics. 05/22 accepted
Melsens K*, Cutolo M*, Schonenberg-Meinema D, Foeldvari I, Leone MC, Badot V, Dehoorne J, Deschepper E, Frech T, Cimaz R, Hernandez-Zapata J, Ingegnoli F, Khubchandani R, Lehman H, Makol A, Mason T, Mesa-Navas MA, Michalska-Jakubus M, Mostmans Y, Müller-Ladner U, Nuno L, Overbury R, Pimpale P, Radic M, Ravelli A, Rosina S, Udaondo Clara, Sulli A, Herrick A, and Smith V; EULAR Study Group on Microcirculation in Rheumatic Diseases. Standardized nailfold capillaroscopy in children with rheumatic diseases: a worldwide study. Rheumatology published 25.08.2022. doi.org/10.1093/rheumatology/keac487
Hermine I Brunner1*, Ivan Foeldvari2, Ekaterina Alexeeva3, Nuray Aktay Ayaz4, Inmaculada Calvo5, Ozgur Kasapcopur6, Vyacheslav G Chasnyk7, Markus Hufnagel8, Zbigniew Zuber9, Grant S Schulert1, Seza Ozen10, Adelina Rakhimyanova11, Athimalaipet Ramanan12, Christiaan Scott13, Betul Sozeri14, Elena Zholobova15, Ruvie Martin16, Xuan Zhu16, Sarah Whelan17, Luminita Pricop16, Alberto Martini18, Daniel J Lovell1 and Nicolino Ruperto19, on behalf of Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial . Ann Rheum Disease epub 14/08/22. 10. 1136/ ard- 2022-222849).
Laura J. Montag1,2, Gerd Horneff3,4, Ivan Foeldvari5, Johannes-Peter Haas6, Eva Seipelt7, Stefanie Tatsis8, Paula Hoff9, Peer Aries10, Ariane Klein3, Martina Niewerth2, Jens Klotsche2† and Kirsten Minden11,2†Medication Burden of Young Adults with Juvenile Idiopathic Arthritis – data from the JIA register JuMBO. RMD open. Accepted 26.09.2022
Dr. Prasad Thomas Oommen, Timmy Strauss, MD; Karen Baltruschat; Ivan Foeldvari, M.D.; Christoph Deuter, MD; Gerd Ganser, MD; Johannes-Peter Haas, MD; Claas Hinze, MD; Dirk Holzinger, MD; Anton Hospach, MD; Hans-Iko Huppertz, MD; Arnold Illhardt; Michael Jung; Tilmann Kallinich, MD; Ariane Klein, MD; Kirsten Minden, MD; Kirsten Mönkemöller, MD; Sonja Mrusek; Ulrich Neudorf, MD; Gregor Dückers, MD; Tim Niehues, MD; Matthias Schneider, MD; Philipp Schoof, MD; Angelika Thon, MD; Michael Wachowsky; Norbert Wagner; Susanne Bloedt; Michaël Hofer, MD; Klaus Tenbrock, MD; Catharina Schuetz, MD. Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): new perspectives on interdisciplinary care. Clin Immunol. 2022 Sep 30:109143. doi: 10.1016/j.clim.2022.109143
Franz Thiele1, Ariane Klein1, 2, Jens Klotsche3, Daniel Windschall4, Frank Dressler5, Jasmin Kuemmerle-Deschner6, Kirsten Minden7, Ivan Foeldvari8, Dirk Foell9, Sonja Mrusek10, Prasad Oommen11, Gerd Horneff1, 2 Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: efficacy, safety and drug survival. Accepted in Rheumatology. 29th of September 2022
Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic3, Maria Teresa Terreri4, Ana Paula Sakamoto4, Valda Stanevicha5, Jordi Anton6, Brian M. Feldman7, Flavio Sztajnbok8, Raju Khubchandani9, Ekaterina Alexeeva10, Maria Katsicas11, Sujata Sawhney12, Vanessa Smith13, Simone Appenzeller14, Tadej Avcin15, Mikhail Kostik16, Thomas Lehman17, Edoardo Marrani18, Dieneke Schonenberg-Meinema19, Walter-Alberto Sifuentes-Giraldo20, Natalia Vasquez-Canizares21, Mahesh Janarthanan22, Monika Moll23, Dana Nemcova24, Anjali Patwardhan25, Maria Jose Santos26, Cristina Battagliotti27, Lillemor Berntson28, Blanca Bica29, Jürgen Brunner30, Rolando Cimaz31, Patricia Costa-Reis32, Despina Eleftheriou33, Liora Harel34, Gerd Horneff35,36, Sindhu R. Johnson37, Daniela Kaiser38, Tilmann Kallinich39, Dragana Lazarevic40, Kirsten Minden39, Susan Nielsen41, Farzana Nuruzzaman42, Siri Opsahl Hetlevik43, Yosef Uziel44, Nicola Helmus1, Kathryn S. Torok45. Gender differences in juvenile systemic sclerosis patients. Results from the international juvenile scleroderma inception cohort. Accepted in Journal of Scleroderma and Related Disorders. 17.11.2022
Ann-Kathrin Hoppe, Suzanne C. Li, Ivan Foeldvari. Validierung des ‚Total Morbidity Scores‘ und Untersuchung der Wirksamkeit von Methotrexat bei der lokalisierten SklerodermieValidation of the ‚Total Morbidity Score‘ and investigation of the efficacy of methotrexate in localized scleroderma. Zeitschrift für Rheumatologie, accepted 11/22.
Kristina Vollbach1, Klaus Tenbrock1, Nobert Wagner1, Gerd Horneff2, Ariane Klein2, Ivan Foeldvari3, Johannes-Peter Hass4, Eva Seipelt5, Heike-Franziska Weidemann6, Peer Aries7, Georg Gauler8, Bettina Wodtke9, Frank Striesow10, Paula Hoff11, Christine Scholz12, Stefanie Tatsis13, Johannes Strunk14, Erich Bärlin15, Jens Klotsche16† and Kirsten Minden16,17† Outcome of adult patients with JIA treated with the biosimilar Benepali. Results of the biologic register JuMBO. Arthritis Research and Therapy, accepted 02.12.2022.
1Broekaert, Ilse*, 1,2Klein, Ariane*, 3Windschall, Daniel, 4Rogalski, Betina, 5Weller-Heinemann, Frank, 6Oommen, Prasad T, 7Küster, Michael, 8Foedlvari, Ivan, 9Minden, Kirsten, 10Hospach, Anton, 11Hufnagel, Markus, 12Berger, Thomas, 13Geikowski, Til, 14Quietzsch, Jürgen, 1,2Horneff, Gerd. Development of Inflammatory Bowel Disease in Children with Juvenile Idiopathic Arthritis Treated with Biologics. Journal of Pediatric Gastroenterology & Nutrition 2023 ; 76, Number 2: 174- 182.
Hermine I. Brunner,1 Nikolay Tzaribachev,2 Ingrid Louw,3 Inmaculada Calvo Penades,4 Francisco Avila-Zapata,5 Gerd Horneff,6 Ivan Foeldvari,7 Daniel J. Kingsbury,8 Maria Eliana Paz Gastanaga,9 Carine Wouters,10 Johannes Breedt,11 Robert Wong,12 Margarita Askelson,13 Joe Zhuo,12 Alberto Martini,14 Daniel J. Lovell,1 and Nicolino Ruperto15 . Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-course Juvenile Idiopathic Arthritis Treated With Abatacept Arthritis Care and Research. Accepted 07.02.2023, DOI 10.1002/acr.25156
Jelena Vojinović1, Ivan Foeldvari,2 Joke Dehoorne3, Violeta Panaviene4, Gordana Susic5, Gerd Horneff6,7, Valda Stanevica8, Katarzyna Kobusinska9, Zbigniew Zuber10, Bogda Dobrzyniecka11, Jonathan Akikusa12, Tadej Avcin13, Cecilia Borlenghi14, Edmund Arthur15, Svitlana Y. Tatulych16, Chuanbo Zang17, Vassilis Tsekouras18, Bonnie Vlahos17, Alberto Martini19, Nicolino Ruperto20 for the Paediatric Rheumatology International Trials Organisation (PRINTO). Ten-Year Safety and Clinical Benefit from the 0pen-Label, Etanercept Treatment in Children and Young Adults with Extended Oligoarticular, Enthesitis-Related, or Psoriatic Juvenile Idiopathic Arthritis. PFIZER (accepted Rheumatology 24.02.2023)
Jens Klotsche 1, Kathryn S. Torok 3, Ozgur Kasapcopur 4, Amra Adrovic 4, Maria Teresa Terreri 5, Ana Paula Sakamoto 5, Maria Katsicas 6, Flavio Sztajnbok 7, Edoardo Marrani 8 Alberto Sifuentes-Giraldo 9, Valda Stanevicha 10, Jordi Anton 11, Brian Feldmann 12, Mikhail Kostik 13, Dana Nemcova 14, Maria Jose Santos 15, Simone Appenzeller 16, Tadej Avcin 17, Cristina Battagliotti 18, Lillemor Berntson 19, Blanca Bica 20, Jürgen Brunner 21, Despina Eleftheriou 22, Liora Harel 23, Gerd Horneff 24, Tilmann Kallinich 25, Kirsten Minden 1,25, Susan Nielsen 26, Anjali Patwardhan 27 , Nicola Helmus 2, Ivan Foeldvari 2. Application and performance of Disease Activity Indices proposed for Patients with Systemic Sclerosis in an International Cohort of Patients with Juvenile Systemic Sclerosis. Journal of Scleroderma and related Disorders. Epub 11.04.23
Saskia N. de Wildt1,2, Ivan Foeldvari3, Angeliki Siapkara4, Pirkko Lepola5, Berit Kriström6, Lucia Ruggieri7, Hide Nakamura8, Gunter Egger9, Irmgard Eichler10.m Off-label is not always off-evidence: Proposal to include more paediatric data in the medicine labels, a proposition by the off-label evidence working group of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) Lancet Child & Adolescent Health accepted 22nd of March,2023.
Hermine Brunner,1 Grant S Schulert,1 Alyssa Sproles,1 Sherry Thornton,1 Gabriel Vega Cornejo,2 Jordi Antón,3 Ruben Cuttica,4 Michael Henrickson,1 Ivan Foeldvari,5 Daniel Kingsbury,6 Margarita Askelson,7 Jinqi Liu,8 Sumanta Mukherjee,8 Robert L Wong,9 Daniel J Lovell,1 Alberto Martini,10 Nicolino Ruperto,10 and Alexei A Grom1 on behalf of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). S100 Proteins as Potential Predictive Biomarkers of Abatacept Response in Polyarticular Juvenile Idiopathic Arthritis. Arthritis Rheum 27th March 2023
S. Johnson, I. Foeldvari . Approach to Systemic Sclerosis Patient Assessment. How Does Patient Subsetting Help?. Rheum Dis Clin North Am. 2023, 49: 193-210.
Jelena Vojinović1, Ivan Foeldvari,2 Joke Dehoorne3, Violeta Panaviene4, Gordana Susic5, GerdHorneff6,7, Valda Stanevicha8, Katarzyna Kobusinska9, Zbigniew Zuber10, Bogna Dobrzyniecka11, Jonathan Akikusa12, Tadej Avcin13, Cecilia Borlenghi14, Edmund Arthur15, Svitlana Y. Tatulych16, Chuanbo Zang17, Vassilis Tsekouras18, Bonnie Vlahos17, Alberto Martini19, Nicolino Ruperto20 for the Paediatric Rheumatology International Trials Organisation (PRINTO. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis. Rheumatology published 4th May 2023. doi.org/10.1093/rheumatology/kead183.
Athimalaipet V Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Šárka Fingerhutová, Jordi Antón, Zhongkai Wang, Gabriella Meszaros, Joana Araújo, Ran Liao, Stuart Keller, Hermine I Brunner, Nicolino Ruperto, on behalf of the JUVE-BASIS investigators and of the Paediatric Rheumatology International Trials Organisation (PRINTO). Baricitinib in juvenile idiopathic arthritis: an international multi-centre phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
Article (Randomised Controlled Trial). Lancet published online 6th of July 2023.doi.org/10.1016/ S0140-6736(23)00921-2
Foeldvari, Ivan; Torok, Kathryn; Klotsche, Jens; Anton, Jordi; Costa-Reis, Patricia; Del Galdo, Francesco; Denton, Christopher; Hinrichs, Bernd; Li, Suzanne; Pain, Clare; Pilkington, Clarissa; Cutolo, Maurizio; Kasapcopur, Ozgur; Khanna, Dinesh; Ruperto, Nicolino; Smith, Vanessa; Furst, Daniel. Proposed response parameters for 12 months drug trial in Juvenile Systemic Sclerosis. Results of the Hamburg International Consensus Meetings. Accepted Arthritis Care and Research 18th of June 2023 accepted. DOI: 10.1002/acr.25171

Übersichtsarbeiten

I. Foeldvari: Antikörper-Diagnostik bei rheumatologischen Erkrankungen im Kindesalter. Deutsches Ärzteblatt 1999,51/52:3288-3290. Impact factor- 2,1
I. Foeldvari: Diffuse and limited cutaneous systemic sclerosis. Current Opinion In Rheumatology, 2000,12:.435-438. Impact factor- 4,497
I. Foeldvari: Kinderrheumatologie. Eine junge Disziplin entwickelt sich. Hamburger Ärzteblatt 2000 , 6-7:258-60. Impact factor- NN
I. Foeldvari, N. Wulffraat: Recognition and management of scleroderma in children. Pediatric Drugs 2001,3:575-583. Impact factor- 1,786
I. Foeldvari: Selektive Cyclooxygenase 2 -Hemmer in der Kinderrheumatologie. Symposium Medical 2002,13:18-19. – Impact factor- NN
I. Foeldvari: Diffuse and limited cutaneous systemic sclerosis. Current Opinion In Rheumatology, 2002,14:699-704. Impact factor- 4,497
I. Foeldvari: Anwendung selektiver COX-2-Hemmer in der Kinderrheumatologie. Rheuma Aktuell, 2002/03:26-27. Impact factor- NN
I Foeldvari: Welche Impfungen sind kontraindiziert? Pädiatrie Hautnah 2003, 15: 226-7. Impact factor Impact factor-NN
I. Foeldvari. TNF- ? Antagonisten in der Kinderrheumatologie. Symposium medical 2004, 15: 32-33.
Impact factor-NN
I. Foeldvari : Systemic Sclerosis in Childhood. Rheumatology 2006, 45: iii28-iii29. Impact factor- 4,171
Arnd Heiligenhaus1#, Gerd Horneff2, Kathrin Greiner3, Friederike Mackensen4, Manfred Zierhut5, Ivan Foeldvari6, Hartmut Michels7 TNF-Inhibitoren bei Arthritis und Uveitis im Kindesalter. Sonderheft der Klinischen Monatsblätter der Augenheilkunde 2007,.224: 526-31. Impact factor- 0,54
I. Foeldvari. Update on juvenile systemic sclerosis. Current Opinion in Rheumatology, 2008, 20: 608-613. Impact factor- 4,497
I. Foeldvari. Current Developments in Pediatric Systemic Sclerosis. Current Rheumatology Report 2009, 11:97 – 102. Impact factor- 0,9
I Foeldvari – Koauthor an den nationalen Leitlinien des Kutanen Lupus Erythematodes. Entwicklungsstufe 1. – www.awmf.org/ www.derma.de – Annegret Kuhn1*, Merle Haust2, Elisabeth Aberer3, Caroline Barde4, Ivan Foeldvari5,Christof Iking-Konert6, Peter Kind7, Alexander Kreuter8, Percy Lehmann9, Thomas Luger1, Jann Lübbe4, Michael Meurer10, Ulf Müller-Ladner11, Falk Ochsendorf12, Vincent Ruland1, Thomas Ruzicka13, Matthias Schneider6, Michael Sticherling14, Beate Tebbe15, Jörg Wenzel16, Annette Wons1, Elke Weisshaar17, Gisela Bonsmann1Kutaner Lupus erythematodes: Teil 1. Diagnostik + Teil 2. Therapie. AWMF Leitlinien Stufe 1..
I Foeldvari, J. Kuemmerle-Deschner. Klinik der autoinflammatorischen Erkrankungen im Kindesalter. Zeitschrift für Rheumatologie 2009,68: 726-732. ISSN 0340-1855. Impact factor- 0,447
T. Constantin, I. Foeldvari . 18 éves életkor alatt alkalmazott anti-TNF támadáspontú biológiai terápiák alkalmazásának protokollja Juvenilis Idiopathias Arthritis indikációban- ( Ungarische Leitlinien zu anti TNF Therapie in Juvenile Idiopathische Arthritis). Immunology Quarterly 2011, 3: 19-22. Impact factor-NN
Carsten Heinz, Arnd Heiligenhaus, Jasmin Kümmerle-Deschner, Ivan Földvari. Uveitis bei juveniler idiopathischer Arthritis (JIA). Zeitschrift für Rheumatologie 2010, 69:411–418 • DOI 10.1007/s00393-010-0656-7. Impact factor- 0,447
I. Foeldvari. Editorial- Arthritis and Rheumatism- Methotrexat in juvenile localized scleroderma. Adding to the evidence. Arth Rheum 2011, 63: 1779-1781. Impact factor- 8,435
Levy RA, de Andrade FA, Foeldvari I. Cutting-edge issues in autoimmune uveitis. Clin Rev Allergy Immunol. 2011 Oct;41(2):214-23. Impact factor- 3,435
I. Foeldvar. H6c „Juvenile systemische Sklerodermie. Leitlinien im Kinder- und Jugendmedizin im Elsevier, Urban & Fischer Verlags Sektion H (Rheumatologie) für das Loseblattwerks. In print 2011- Impact factor- NN
Dr. Constantin Tamás, Dr. Foeldvari Iván. 18 éves életkor alatt alkalmazott anti-TNF támadáspontú biológiai terápiák alkalmazásának protokollja Juvenilis Idiopathias Arthritis indikációban. Immunológiai Szemle. 2011; 1: 19-30. Impact factor- NN
I. Foeldvari. New developments on the topics of Juvenile Systemic and Localized Scleroderma . Rheumatic Disease Clinics of North America. 2013 in print. Impact factor: 2.950
I. Foeldvari. Update zur juvenilen systemischen Sklerodermie. Arthritis + Rheuma 2013, 33: 114-117
A. Kienast. I Foeldvari. Hauterscheinungen bei rheumatischen Erkrankungen im Kindes und Jugendalter. Kinder- und Jugendarzt 2013, 44, 149-156.
I. Foeldvari. Current concepts in uveitis associated to juvenile idiopathic arthritis. Clinical Reviews of Allergy and Immunology. 2014, published online 01.08.2014. Impact factor 4.728
Tamas Constantin, Gyorgyi Zoltan, Ivan Foeldvari, Peter Weiser, Andras Szabo Recent advance in Systemic Scleroderma in Childhood. Annals of Paediatric Rheumatology. Accepted APR-2014-08-018.
I. Foeldvari Update on Juvenile Systemic Sclerosis. Current Rheumatology Reports. 2015, 17:18.
I Foeldvari…. Guideline on the treatment of sclerosing diseases of the skin. Developed by the Guideline Subcommittee of the European Dermatology Forum. 2016
I Foeldvari. Managing uveitis in patients with juvenile idiopathic arthriits. Expert Opinion on Orphan Drugs. Accepted 07th April 2016.
I. Foeldvari . Scleroderma in childhood: Systemic form – Evaluation and Management – Chapter in Pediatric Rheumatology: A Clinical Viewpoint. Springer Verlag 2016.
Ivan Foeldvari¹, Karoline Walscheid², Arnd Heiligenhaus^2,3 Uveitis bei juveniler idiopathischer Arthritis. Zeitschrift Rheumatologie epub 15.08.17
Knobler, R; Moinzadeh, P; Hunzelmann, N ; Kreuter, A; Cozzio, A ; Mouthon, L; Cutolo, M; Rongioletti, F; Denton, C P; Rudnicka, L; Frasin, L A; Smith, V; Gabrielli, A; Aberer, E; Bagot, M; Bali, G; Bouaziz, J; Braae Olesen, A; Foeldvari, I; Frances, C; Jalili, A; Just, U; Kahari, V; Karpati, S; Kofoed, K; Krasowska, D; Olszewska, M; Orteu, C; Panelius, J; Parodi, A; Petit, A; Quaglino, P; Ranki, A; Sanchez Schmidt, J M; Seneschal, J; Skrok, A; Sticherling, M; Sunderkotter, C; Taieb, A; Tanew, A; Wolf, P; Worm, M; Wutte, N J; Krieg, T. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol. 09 August 2017.
Knobler, R; Moinzadeh, P; Hunzelmann, N ; Kreuter, A; Cozzio, A ; Mouthon, L; Cutolo, M; Rongioletti, F; Denton, C P; Rudnicka, L; Frasin, L A; Smith, V; Gabrielli, A; Aberer, E; Bagot, M; Bali, G; Bouaziz, J; Braae Olesen, A; Foeldvari, I; Frances, C; Jalili, A; Just, U; Kahari, V; Karpati, S; Kofoed, K; Krasowska, D; Olszewska, M; Orteu, C; Panelius, J; Parodi, A; Petit, A; Quaglino, P; Ranki, A; Sanchez Schmidt, J M; Seneschal, J; Skrok, A; Sticherling, M; Sunderkotter, C; Taieb, A; Tanew, A; Wolf, P; Worm, M; Wutte, N J; Krieg, T. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol. 08 August 2017.
I. Foeldvari: Rheumatologische Differentialdiagnostik bei Uveitis im Kindesalter. Aktuelle Rheumatologie. 2019; 44: 1-5.
I. Foeldvari : Update on the systemic treatment of pediatric localized scleroderma. Pediatric Drugs. 2019,21: 461-467. DOI: 10.1007/s40272-019-00363-5
I. Foeldvari: Besonderheiten der Juvenilen Systemischen Sklerodermie. Pädiatrische Praxis 2020, 94 1-7.
Diagnostil und Therapie des kutanen Lupus Erythematodes. S2K Leitlinien. AWMF-Regiser-Nr.:Registernummer 013-060,2020 . Leitlinienkoordnation: Prof. Dr. Margitta Worm. Koauthor Ivan Foeldvari
Juvenile Systemic Sclerosis – Updates and practice points. Ivan Foeldvari, Cassie Took. Best Practice in Clinical Rheumatology 03/21 accepted. DOI 10.1016/j.berh.2021.101688
M;.Worm1, Miriam Zidane2, Lisa Eisert3, Rebecca Fischer-Betz4, Ivan Foeldvari5, Claudia Günther6, Christof Iking-Konert7, Alexander Kreuter8, Ulf Müller-Ladner9, Alexander Nast2, Falk Ochsendorf10, Matthias Schneider4, Michael Sticherling11, Klaus Tenbrock12, Jörg Wenzel13, Annegret Kuhn14 . S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes – Teil 1: Klassifikation, Diagnostik, Prävention und Aktivitätsscores . JDDG, 2021 , DOI: 10.1111/ddg.14492_g
Margitta Worm1, Miriam Zidane2, Lisa Eisert3, Rebecca Fischer-Betz4, Ivan Foeldvari5, Claudia Günther6, Christof Iking-Konert7, Alexander Kreuter8, Ulf Müller-Ladner9, Alexander Nast2, Falk Ochsendorf10, Matthias Schneider4, Michael Sticherling11, Klaus Tenbrock12, Jörg Wenzel13, Annegret Kuhn1 S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 1:Classification, diagnosis, prevention, activity scores. JDDG, 2021 DOI: 10.1111/ddg.14492 .
Heiligenhaus A1, Minden K2, Tappeiner C1, Baus H5, Bertram B3, Deuter C1, Foeldvari I2, Föll D2, Frosch M2, Ganser G2, Gaubitz M4, Günther A2, Heinz C1, Horneff G2, Huemer C2, Kopp I6, Lutz T2, Michels H2, Neß T1, Neudorf U2, Pleyer U1, Schneider M4, Schulze-Koops H4, Thurau S1, Zierhut M1, Lehmann HW. Interdisziplinäre Leitlinie zur Diagnostik und antientzündliche Therapiue der Uveitis bei juveniler idiopathischer Arthritis. AWMF-Registernummer: 045-012. 2021
Foeldvari I. Juvenile systemische Sklerodermie. Arhtritis+Rheuma 2022, 05: 346-352. DOI10.1055/a-1895-3963
Foeldvari Ivan, Marrani Edoardo. Systemic therapy in juvenile localised scleroderma“ has been accepted for publication in Expert Review of Clinical Immunology. Accepted 13.07.2023. Published 18.07.23 .DOI: 10.1080/1744666X.2023.2237685; ISSN: 1744-8409

Beiträge zu Fachbüchern

C. Loeliger, I Foeldvari: Caucasian German juvenile rheumatoid arthritis. In P.I. Terasaki, D.W. Gjertson, Herausgeber. HLA 1997. Los Angeles: UCLA Tissue Typing Laboratory; 1997:407-8.
M. Girschick, I. Foeldvari: Systemische Sklerose, progressive systemische Sklerodermie. In: Leitlinien der Kinderheilkunde und Jugendmedizin. München, Urban und Fischer; 1999:H7:36-39
I. Foeldvari, E. Weissbarth-Riedel: Wegener Granulomatose und seltene Vaskulitiden. In: Leitlinien der Kinderheilkunde und Jugendmedizin. München, Urban und Fischer; 1999:H7:46-51
Gromicka,-Ihle, I. Foeldvari. Phospholipidsyndrom. In: Rheumatische Erkrankungen im Kindes- und Jugendalter. München: Hans Marseille; 2001:274-286
I. Foeldvari: Sklerodermie. In Rheumatische Erkrankungen des Kindes- und Jugendalter. München: Hans Marseille; 2001:296-303.
I. Foeldvari, T. Niehues: Leitlinien zur Anwendung der Nicht Steroidalen Antirheumatika in der Kinder- und Jugendrheumatologie. Für die Leitlinien der Kinderheilkunde und Jugendmedizin. (2004
G. Horneff, I. Foeldvari: Leitlinien zur Anwendung der Tumor Nekrosis- Alfa Blocker in der Kinder- und Jugendrheumatologie. Für die Leitlinien der Kinderheilkunde und Jugendmedizin. (2004)
I. Foeldvari, H. Girschick: Leitlinien zur Diagnose und Therapie der systemischen Sklerodermie. Für die Leitlinien der Kinderheilkunde und Jugendmedizin. (2004)
I. Foeldvari. Sklerodermie und Sharp-Syndrom im “N. Wagner und G. Dannecker : Pädiatrische Rheumatologie- Buch, Springer 2007: 347-363.
I. Foeldvari. Juvenile Systemic Sclerosis. Im Handbook of Systemic autoimmune diseases- Pediatrics. – First Edition – Elsevier 2008. 107-118. Herausgeber: T. Lehmann und R. Cimaz.
Foeldvari. An 8-year-old girl with tight skin, digital ulcers, and dysphaiga. Case Studies in Systemic Sclerosis. Editors: Richard M. Silver and Christpher P. Denton. Springer 2011.
I. Foeldvar. Juvenile systemic sclerosis. Page 93-103. Scleroderma – From Pathogenesis to comprehensive management. Editors J. Varga, C.P. Denton, F.M. Wigley. Springer 2012.
I. Foeldvari. Sklerodermie und Sharp-Syndrom im “N. Wagner und G. Dannecker : Pädiatrische Rheumatologie- Buch, Springer 2013- in print
Foeldvari, K. Reich Skin Manifestations of Neonatal Lupus Erythematosus. Part IV- Chapter 25. Page 201. Skin Manifestation in Rheumatic Diseases. 1st Edition Springer 2013 – Herausgeber: Matucci-Cerinic
I. Foeldvari. Up Date on Juvenile Systemic Sclerosis. Ebook chapter. Cutolo et al. 2013. Future in Medicine.
Arnd Heiligenhaus, Christoph Tappeiner1, Carsten Heinz, Ivan Foeldvari, Kapitel. 5.5. Juvenile idiopathic arthritis. Uveitis. Editor. Manfred Zierhut in print
I. Foeldvari . Scleroderma in childhood. Manual in Pediatric Rheumatology. Ebook. Editor S. Sawhney and A. Aggarwal.
Kienast A1, Foeldvari I1. Sklerodermie im Kindes- und Jugendalter: Diagnose, Behandlung und Prognose (Scleroderma in children and adolescents). Pädiatrische Praxis 2015, 84.319-328.
Foeldvari I, Ponya A. Scleroderma Spectrum Korkepie. Klinikai gyermekgyógyászat (Buch) 13. Chapter ( 2016) :266-269.
I Foeldvari. Juvenile systemic Sclerosis. Pediatrics in Systemic Autoimmune Diseases. ISBN 978-0-444-63596-9. 2nd edition 2016:249-266.
Aktualisierte, interdisziplinäre S2k-Therapieleitlinie Interdisziplinäre Leitlinie zur Diagnostik und antientzündlichen Therapie der Uveitis bei juveniler idiopathischer Arthritis AWMF-Registernummer: 045-012 . Koauthor Ivan Foeldvari (2017)
Aktualisierte, interdisziplinäre S2k-Therapieleitlinie der Juvenilen Idiopathischen Arthritis (3. Auflage, 2019). Koauthor Ivan Foeldvari
Diagnostik und Therapie des kutanen Lupus erythematodes AWMF-Register-Nr.: Registernummer 013 –060, 2019. Koauthor Ivan Foeldvari
Sklerodermie bei Kindern und Jugendlichen. Buchkapitel im „Pädiatrische Rheumatologie“ Herausgeber Norbert Wagner, Günther Dannecker und Tillmann Kallinihc. 2020 bei Springer Verlag
Juvenile systemische und lokalisierte Sklerodermie. Buchkapitel im „Praktische Kinder- und Jugendrheumatologie“ Herausgeber Gerd Horneff und Kirsten Minden. 2020 De Gruyter Verlag.
Juvenile idiopathsiche Arthritis assoziierte Uveitis. Buchkapitel im „Praktische Kinder- und Jugendrheumatologie“ Herausgeber Gerd Horneff und Kirsten Minden. 2020 De Gruyter Verlag.
Sklerodermie bei Kindern und Jugendlichen. Im N. Wagner et al. (Hrsg.), Pädiatrische Rheumatologie, Springer Reference Medizin, 2021. 10.1007%2F978-3-662-60411-3_41-1

Einladungen zu Vorträgen

Mai-Symposium der Rheumaklinik Wiesbaden II, Abklärung weichteilrheumatischer Symptome bei Kindern. (5/1995)
Universitätskinderklinik Essen: „Rationelle diagnostische Nutzung von Autoantikörpern bei rheumatischen Erkrankungen im Kindesalter”. (6/1996)
Universitätskinderklinik des Virchow-Klinikums, Berlin: „Rationelle diagnostische Nutzung von Autoantikörpern bei rheumatischen Erkrankungen im Kindesalter”.(7/1996)
Fortbildungsabend der Vereinigung der Kinderärzte Hamburg e.V.: Untersuchung des rheumakranken Kindes in Praxis und Labor. (5/1997)
Ärztlicher Verein, Fortbildungsakademie, Fortbildungsabend: Untersuchung von Kindern mit muskuloskeletalen Beschwerden in Praxis und Labor. (12/1997)
Nycomed Pharma Rheumasymposium 1998, Oslo, Norwegen, Übersichtsvortrag: Sclerodermia, Prevalence, Diagnosis, Treatment. (4/1998)
Fifth International Workshop on Scleroderma Research, July 19-21, 1998 Boston, Massachusetts, unterstützt vom National Institute of Health: „Survival in Pediatric Scleroderma“.
Veranstaltung des Norddeutschen Zentrums zur Weiterentwicklung der Pflege: “Kinder-Welt”, workshop: „Diagnose: Lebenslänglich” (11/98).
Interdisziplinäres Symposium, Universtitäts-Krankenhaus Eppendorf: „Nichtsteroidale Antirheumatika: Erkennung und Vermeidung unerwünschter Wirkungen.: Das Kind als Rheuma- Patient: Wo liegen die besonderen Probleme?“. (1999)
Regionaltagung der Deutschen Gesellschaft für Rheumatologie, Warnemünde, 1999: Organisation und Vorsitz des Symposium der Arbeitsgemeinschaft Kinderrheumatologie, „Rationale Diagnostik der Gelenkbeschwerden im Kindes- und Jugendalter“ (Vortrag zusammen mit Dr. Dressler) (Zeitschrift für Rheumatologie, 1999, 58 (Suppl 1):I/19 S 44).
„Transition Clinics für adoleszente Patienten“.
Der besondere Fall. Aplastische Anämie und Thrombotische Thrombozytopenische Purpura bei einer Patientin mit systemischem Lupus erythematosus. Symposium der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie und der Niederländischen Arbeitsgemeinschaft Pädiatrische Rheumatologie. 21.01.2000, Sendenhorst.
Scleroderma in Childhood. An Overview. National Paediatric Rheumatology Teaching Course at Great Ormond Street Hospital, in Cooperation with The Institute of Child Health, 02.24.2000, London, UK.
Juvenile systemic sclerosis. An overview. Grand rounds. Children´s Hospital of Phialdelphia, University of Pennsylvania, Philadelphia, USA. 27. 03.2000.
Results of the Phase I/II Study for Meloxciam, International Investigator Meeting Meloxicam, Boehringer Ingelheim, 02/02/2001, München, Germany.
Juvenile systemic sclerosis and outcome. First International Workshop on Juvenile Scleroderma. 1-3 June 2001, Padua, Italy
Juvenile Systemic sclerosis outcome and treatment. 01.08.2001, Rheumatology Rounds, Department of Immunology and Rheumatology, Childrens Memorial Hospital, Nortwestern University, Chicago, IL, USA
Erste Ergebnisse der Anwendung von selektiven COX-2-Hemmern in der Kinderrheumatologie. 21.09.01, 30. Kongress der Deutschen Gesellschaft für Rheumatologie, Leipzig. Zeitschrift für Rheumatologie, 2001, 60, Suppl 1: I/16.
Systemischer Lupus Erythematodes bei Neugeborenen und im Kindesalter. Veranstaltung zum 10-jährigen Jubiläum der Regionalgruppe Hamburg, LUPUS Erythematodes – Selbsthilfegemeinschaft. e.V. 24.08.02, Hamburg.
COX-2 Hemmer bevorzugt? Eine kritische Bestandsaufnahme. Mittagssymposium, Deutscher Orthopädenkongress 2002 Berlin.
Corticoidinduzierte Osteoporose bei juveniler rheumatoider Arthritis. Seminar des Regionalen Expertenkreises Osteoporose – Mitteldeutschland, 16.11.2002, Hannover.
Juvenile Systemische Sklerodermie. 6. Kurs Pädiatrische Rheumatologie, 22.-23.11.2002, Bremen.
Ambulante Versorgung rheumakranker Kinder. Symposium Rheuma bei Kindern – Neue Wege. Universitätskinderklinik Greifswald 08.02.2003.
Immunsuppressive Therapie bei der kindlichen Uveitis. Fortbildung zum Thema Uveitis- aktuelle Aspekte. Universitäts-Augenklinik Hamburg-Eppendorf, 22.02.2003.
Results of treatment with methotrexate for uveitis associated to juvenile idiopathic arthritis. Grand rounds. Rheumatology Department,MUSC, Charleston, South Carolina, 20.03.2003.
Juvenile systemic sclerosis: clinical and laboratory features and outcome. Grand rounds, University Children´s Hospital, Padua, Italien, 30.05.2003.
Klinische Präsentation, Therapie und Prognose der kindlichen systemischen Sklerodermie. 13. Jahrestagung der Arbeitsgemeinschaft für Kinder und Jugendrheumatologie. Aktuelle Rheumatologie, 2003, 28: 279, E.1.
Pediatric skin scoring. OMERACT 7, 2004, Monterey , California, USA.
Labordiagnostik von Autoimmunerkrankungen im Kindesalter. – Workshop – 12. Jahrestagung der Arbeitsgemeinschaft Pädiatrische Dermatologie, 09/2004.
Sklerodermie im Kindesalter. Wörlitzer Gespräche, 02.10.2004.
Update on uveitis treatment . National Brasilian Rheumatology Meeting, October 2004, Rio de Janeiro, Brasil.
Scleroderma in children. Nationale Brasilian Rheumatology Meeting, October 2004, Rio de Janeiro, Brasil.
Juvenile systemic sclerosis: Presentation of the planned inception cohort project. 1st Joint Cooperation Meeting of the German Network for Systemic Sclerosis (DNSS), Scientific Advisory Board, Köln, 17-18. December 2004.
Das Hamburger Diagnostik- und Therapiekonzept für Kinder und Jugendliche mit juveniler idiopathischer Arthritis. 21.001.2005, Universitätsklinikum Hamburg-Eppendorf, Zentrum für Zahn-, Mund- und Kieferheilkunde.
Scleroderma: how will we now learn more about this rare disease? – Old Challenges and New Directions in pediatric Rheumatology“ – Ross Petty Tribute Symposium 02.04.2005, Vancouver, Canada.
Aktuelle Aspekte der Uveitisbehandlung bei Kindern – Immunomodulation. Am 22.06.2005- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Augenheilkunde.
Formen der Sklerodermie im Kindesalter- Guide zum praktischen Vorgehen- Symposium Kinder- und Jugendrheumatologie- am 10.09.05 Klinik Sankt Augustin, Sankt Augustin.
Sklerodermie im Kindesalter. 4. Erfurter Symposium – Autoimmunerkrankungen im Kindes und Jugendalter. 05.11.2005, Erfurt.
Juvenile idiopathische Artritis – Therapie der Uveitis assoziiert zu JIA. Uveitis Seminar der Deutschen Arbeitsgemeinschaft für Uveitis und der Uveitis Selbsthilfegruppe in Zusammenarbeit mit der Universitäts Augenklinik Hamburg Eppendorf. 26.-27.11.2005 Hamburg.
The eye in systemic disease – Is there an effective immunopsuppressive treatment for juvenile idiopathic arthritis associated uveitis? – II Congresso Latino-Americano De Autoimmunidade, Rio de Janiero, 28-30.04.2006, Brasilien.
Sklerodermie – Seminar – im Rahmen der Netzwerk seltene Krankheiten: Beispel Bindegewebe. MEDICA 2006, 17.11.06 Düsseldorf
Systemic Sclerosis in childhood – Professor E. Carwile LeRoy Memorial International workshop on Scleroderma. 17.-20.05.2007 , Tokyo, Japan.
What makes children so spezial as patients? – Workshops on inflammatory disese in childhood: future challenges in paediatric uveitis. Annual Meeting of the European Society of Ophthalmology and the American Academy of Opthalmology. Wien 12.06.07.
Juvenile Sklerodermie. 35. Kongress der Deutschen Gesellschaft für Rheumatologie, Hamburg, 19.-22.09.2007.
Juvenile Skleroderma – DROP 2007 . Debrecen. Ungarn.. 16.11.2007.
Therapie der juvenilen idiopathischen Arthritis. –Plenary Session- Jahresversammlung der ungarischen Kinderrheumatologen. Budapest. Ungarn. 01.12.,2007.
Systemic Sclerosis World Symposium. Pediatric workshop- Clinical Presentation of juvenile systemic sclerosis . Organised by Actelion. Paris,France- 02.2008
Diagnose und Behandlung der juvenilen idiopathischen Arthritis assoziierten Uveitis.
25.04.2008, Barcleona. I. Reunion Nacional. Uveitis asociade a Arthritis Idiopatica Juvenil.
Skin scores: what it tells us in adults in children. Invited speaker for the 15th Paediatric Rheumatology European Sociatey Congress. London 14.-17.09.2008.
Systemic Sclerosis World Symposium. Pediatric workshop- Clinical Presentation of juvenile systemic sclerosis . Organised by Actelion. Basel,Switzerland. 27.02.-01.03.2009.
Experts Meeting 2009- Evolving Concepts and treatment practices in systemisc IL-1ß-driven autoinflammatory disease. – Speaker- Ensuring more accurate diagnosis and better patient management through referrals. Organised by Novartis. Zürich, Switzerland. 08.-09.05.2009
2. Symposium – “Sport & Rheuma bei Kindern”- JIA: Wie sollen wir bei der Sport-Beratung vorgehen?- Garmisch-Partenkirchen, 09.05.09.
Biologics in JIA. Kolloquium- The Impact if Biologics in the treatmet of arthritis. Technische Universität Zürich, Schweiz 01.10.09. I. Foeldvari. Bilogics in JIA.
Sklerodermie und Kollagenosen –ZNS- Komplikation im Kindes- und Jugendalter.- Halle 26.02.10.- Symposium- Pädiatrische Neuromimmunologie“.
Rheumatologische Diagnositik für benachbarte Fachdisziplinen. 2. Kieler CMD Konferenz – 19.-20.03.10.
Diagnostik und Therapie aus rheumatologischer Sicht. XV. Kongress der German Board of Orthodontics and orofacial Orthopedics. Bonn. 17.-18.04.10
Scleroderma – Diagnosis and Medical Managements and Uveitis Diagnosis and Managment at the Advaced Pediatric Rheumatology Course at Great Ormond Street Hospital, UK . 02.07.2010
Faculty on the EUSTAR/EULAR course for the lecture: juvenile systemic scleoris, Belgrad, Serbia, 2011.
Outcome Measures in Uveiits associated to juvenile idiopathic Arthritis. PRES Meeting Valencia 9.-12 09.2010.
Besonderheiten und Languzeitprognose der juvenilen systemischen Sklerodermie. Übersichtsreferat. DGRH Kongress Hamburg 2010
Enviromental influence on clinicla picture of FMF. 2 nd International Education meeting on Peridoidc Fever Syndromes and autoinfalmmatrory diseases. Budapest, Hungary. 22nd of October 2011.
The TMJ survey results- how pediatric rheumatologists approach TMJ arthritis. 3rd Conference on TMJ Arthrritis in Children with Juveniler Idiopathischer Arthritis. 15-16.04.2011 Kiel, Germany
Adaptation and Validation of Outcome Measures for Pediatric Uveitis. Pediatric Rheumatology study group at the American College of Rheumatology Meeting. 2011 Chicago, USA.
Specific features of juvenile scleroderma. Annual meeting of the Groupe Francais de Recherche sur la Sclerodermie. 22nd of November 2011, Paris, France.
Juvenile Scleroderma. Patient Programm. 2 nd Systemic Sclerosis World Congress, 02.-04.2012, Madrid . Spain
Faculty on the EUSTAR/EULAR course for the lecture: juvenile systemic scleoris, Cluj, Romanie, 2013.
How to access systemic treatment efficacy in juvenile idiopathic arthritis associated arthritis. Plenary session talk. Second International congress on Controverises in Rheumatology & Autoimmunity (CORA) meeting, Budapest 2013.
Juvenile Scleroderma. Patient Programm. 2 nd Systemic Sclerosis World Congress, 02.-04.2012, Madrid . Spain
Faculty on the EUSTAR/EULAR course for the lecture: juvenile systemic scleoris, Cluj, Romanie, 2013.
How to access systemic treatment efficacy in juvenile idiopathic arthritis associated arthritis. Plenary session talk. Second International congress on Controverises in Rheumatology & Autoimmunity (CORA) meeting, Budapest 2013.
Sklerodermie: Neue Therapien und deren Risiken- besondere Aspekte für juvenile systemische Sklerodermie. DGRH /GKJR Kongress – Mannheim 20.09.2013.
Activity and damage – We have to measure them- Juvenile Systemic Sclerosis. Plenary Session talk. Annual Pediatric Rheumatology European Society Meeting 28th of September, Ljubjana, Slovenia.
Arthritis, Juvenile idiopathische Arthritis. Kompaktkurs Kinderorthopädie der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie. 12.-15.11.13 Hamburg
Kinderophthalmologie Symposium- am 07.12.13, Universitäts Augenklinik Hamburg. Juvenile Idiopathische Arthritis assozierte Uveitis – Outcome measures und Therapie aus kinderrheumatologischer Sicht
39. Garmisch-Partenkirchner Symposium für Kinder- und Jugendrheumatologie. Juvenile Sklerodermie- ein Update. 18.01.2014.
3. Systemic Sclerois World Congress , Rome, Italy 2014: Systemic involvement in localised scleroderma.
3. Systemic Sclerois World Congress , Rome, Italy 2014: Is juvenile systemic sclerosis a diferent disease from the adult onset disease? Clinical outcome data.
3. Systemic Sclerois World Congress , Rome, Italy 2014 – Patient Programm: Juvenile Scleroderma.
Annual Russion Meeting of Pediatric, Moscau, Russia 15.02.14: Methotrexate in Juvenile Rheumatic Diseases.
Annual Meeting of European Society Pediatric Dermatology (ESPED) 14.06.2014 Kiel- Rheumatic Disease…. Skin.
2nd South-East Europe (SEE) course in adult an Pediatric Rheumatology , 16-18.0914, Belgrade, Serbia- Uveitis – State of the Art
2nd South-East Europe (SEE) course in adult an Pediatric Rheumatology , 16-18.0914, Belgrade, Serbia- Systemic Scleroderma in Childhood
Annual Pediatric Rheumatology European Sociaty Meeting. Belgrad, 17.-21.09.2014. Outcome measures in JIA associated Uveitis.
Brasilian Rheumatology Meeting, Bella Horisonte , 1.-4.10.2014. Review of juvenile Scleroderma.
Brasilian Rheumatology Meeting, Bella Horisonte , 1.-4.10.2014. Review of treatment of uveitis.
Kongress Deutsche Gesellschaft für Transitionsmedizin, Kiel 27.-28.11.2014. Transtion in der Kinder- und Jugendrheumatologie in Hamburg. Stefanie Tatsis und Ivan Foeldvari
EULAR 2015 Rome, 10-13.06.2015. Juvenile systemic sclerosis. Plenary session talk.
EULAR 2015 Rome, 10-13.06.2015. Scleroderma like fibrosing diseases. Plenary session talk.
DGRH Kongress Bremen 02.-05.09.15. Therapierefraktäre Uveitis. Plenary session.
1st Central European Basic Course in Pediatric Rheumatology, Budapest Hungary 26-29th of November, 2015. Juvenile Scleroderam , Raynuad Phenomenon. Plenary Session talk.
XIX Congress of Pediatricians of Russia. Mokva 12-14th of February, 2016. Plenary session in Actual Problems of Pediatrics. Methotrexate usie in juvenile rheumatic diseases.
4th Systemic Sclerosis World Congress, 18-20th Februaray 2016, Lissabon. Session Localised Scleroderma Diagnosis, Classification and Therapy. Selected case presentation difficult treatment decisions.
4th Systemic Sclerosis World Congress, 18-20th Februaray 2016, Lissabon. FESCA session: Juvenile Scleroderma.
7th EULAR course on Capillaroscopy 8-10th of January 2016, Genua, Italy. Raynaud Phenomenon in Children.
19. PReS Advanced Educational Course Juvenile idiopathic arthritis. Ljubljana, Slovenia. 17th-19th March, 2017. Efficacy and safety of MTX and other DMARDs
19. Komplikationen bei der Erkrankung mit kindlicher Sklerodermie Risikofaktoren für einen schwereren Verlauf. DGRH plenary session. Stuttgart 7th – 10th of September, Stuttgart Germany.
19. Aktuelles zu Diagnose, Differentialdiagsnose und Therapie der Uveitis. Aus Sicht der Kinderrheumatologen. Hamburger Augenärztliche Fortbildung am UKE. 16.09.17. Hamburg, Germany.
Juvenile idiopathic arthritis associaeid uveitis from the perspective of the Pediatric Rheumatologist. In tema di Malattie rare Pediatriche. Uveite infiammatorica cronica dellìnfanzia: un pradigma. 05.12.17 Fondazione Meyer, Florence, Italy.
„Use of Biologics in Paediatric Rheumatology“ . „JIA associated Uveitis“ and „Approach & Management of musculoskeletal Pain in children“. Solo Speaker on the Paediatric Rheumatology Symposium by The Hong Kong Society of Paedaitric Rheumatology.Invited Speaker, 27.01.2018, Hong Kong.
Presentation of juvenile systemic sclerosis and difference to adult patients. Scleroderma Family day 18.01.2018 at the Royal Free Hospital , London, UK
Resultados da coorte internacional de escleroderma. XXXV. Brasilian Rheumatology Congress .08.09.2018 Rio de Janeiro, Brazil.
Share Recommendation for juvenile Scleroderma. Brasilian Rheumatology Congress, 08.09.2018 Rio de Janeiro, Brazil.
Diagnostico de escleroderma na infancia. Brasilian Rheumatology Congress , 08.09.2018 Rio de Janeiro, Brazil.
Raynaud´s in Childrens: the size of the problem and new guidelines. 8 th EULAR course of capillaroscopy in Rheumatic Diseases. 13-15th of September, 2018, Genua, Italy.
Uveitis in Childhood. APLAR 08.-12 th of April 2019, Brisbane, Australia.
Scleroderma in Childhood. APLAR 08-12th of April 2019, Brisbane , Australia.
Juvenile systemic and localised Scleroderma. FESCA session. World Scleroderma Congress-e. July 12-14th 2020.
Mixed connective tissue disease in children – “A myth or a reality”- British Society for Rheumatology Case Based Conference – 14 th of October 2020.
Juvenile Systemic Scleroderma. An educational plenary talk on zoom for the Indian Pediatric Rheumatology Society 19th of December 2020.
Haut, Fieber und Gelenke. 29. Jahrestagung der Arbeitsgemeinschaft Pädiatrische Dermatologie e.V. in der DDgG 06.03.2021.
Juvenile Systemic Sclerosis. Plenary session talk. Virtual meeting. Annual Meeting of The Mexican College of Rheumatology. 17 th of May 2021.
Juvenile Scleroderma. Plenary session talk. Virtual Meeting. 23. Pan-American Congress of Rheumatology. PANLAR 2021. August 12th to 15th 2021.
Juvenile Scleroderma. Plenary session talk. Virtual Meeting 4th Chinese Sclerodema Congress Ocober 1st -2nd 2021 .
Juvenile Sklerdermie- Interdisziplinäre Versorgung. Plenary session talk. Kongress der Deutschen Gesellschaft für Kinder- und Jugendrheumatologie. Berlin, 06-09.10.2021
Juvenile Systemic Sclerosis. XXXII Curso International de Rheumatologia . 21.10.2021 Sociedad Peruana De Rheumatologia.
Updates in Juvenile Systemic Sclerois. Organ Specific Issues. Plenary session talk. Virtual Meeting of the Annual Meeting of the American College of Rheumaology ,5th to 10 th of November, 2021, San Francisoc USA.
Diagnosis and treatment of Juvenile Localized Sclerodermia. 50h Mexican Congress of Rheumatology. March 10th-15th, 2022.
What parents should know about good clinical assessment in juvenile systemic scleroderma. FESCA session of he World Scleroderma Congress, 11th of March 2022.
Managing many faces of systemic sclerosis: skin diseases and gastrointestinal effects. JIR virtual Winterschool 2022 on Management of Connective Tissue Diseases – March 18-19, 2022
Juvenile systemic sclerosis: differences and similarities. EUSTAR/WSF Systemic Virtual School 01.-02.April 2022
Juvenile Scleroderma. A rare condition. 2nd Pediatric Society of the African Leauge against Rheumatism (PAFLAR) meeting 30.06.2022
Was tun, was lassen? Systemtherapie bei lokalisierten Sklerodermie. Deutsche Rheumatologiekongress 2022, 31.08.-03.09.2022, Berlin, Germany
Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent SHARE consensus guidelines. American College of Rheumatology Meeting (ACR) 2022, 12.11.2022 , Philadelphia , USA.
Juvenile systemic sclerosis – update & consensus recommendations. Plenary session talk. 24 th Asia-Pacifc League of Associations for Rheumatology Congress. 6.9th of Decmeber 2022,. Hongkong, China.
Localized Scleroderma. What is the indication for systemic therapy. . 3nd Pediatric Society of the African Leauge against Rheumatism (PAFLAR) meeting . 26.04.2023. Hybrid- Online presentation.
Lessons from the international Juvenile Scleroderma Inception Cohort. Annual meeting of Pediatric Rheumatology European Sociaty , 29th of September, 2023, Rotterdam Holland.

Vorträge auf Kongressen

J. Dippel, I. Foeldvari: Therapie der Juvenilen Polyartikulären Chronischen Arthritis. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde, Ulm 1989.
I. Foeldvari, Y. Kimura, J.C. Jacobs: Macht Komplementdefizienz anfällig für SLE im Kindesalter? 1. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Göttingen, 1991.
I. Foeldvari: Häufigkeit von Antiphospholipid-Antikörpern bei kinderrheumatologischen Patienten. 2. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Göttingen, 1992.
I. Foeldvari, C. Loeliger: Auffällige Häufung von Antiphospholipid-Antikörpern bei Eltern von Kindern mit juveniler oligoartikulärer Arthritis und SLE und deren Korrelation mit HLA-Loci. Vortrag zur 89. Jahrestagung der Kinderheilkunde Würzburg. Monatsschrift der Kinderheilkunde, 1993,141: (Supplement 1) 051 .
I. Foeldvari, N. Birdi, P.B. Dent, R. Elborgh, F. Falcini, R. Häfner, R. Joos, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Outcome of progressive systemic sclerosis (PSS) in childhood: Results of a multi-national questionnaire. (präsentiert zur “3. European Conference on Pediatric Diseases and Allied Disorders, 9/1995; Gent, Belgium. Clin Exp Rheumatol 1995;13: 554.
I. Foeldvari, U. N. Birdi, P.B. Dent, R. Elborgh, F Falcini, R. Häfner, R. Joos, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Progressive Systemische Sklerodermie (PSS) bei 94 Kindern: Ergebnis einer multinationalen Studie. Vortrag zur 5. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Freiburg i.Br., 1995, Monatsschrift Kinderheilkunde 1995; 143: 1052 V18.
I .Foeldvari, C. Soost, R. Klein, C. Loeliger: Assoziation des Auftretens von Antiphospholipid-Antikörpern mit HLA-Merkmalen bei Kindern mit rheumatologischen Erkrankungen und ihren Eltern. Vortrag zur 6. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Mühlheim an der Ruhr, 1996. Monatsschrift der Kinderheilkunde 1996; 144:1295.
I. Foeldvari, M. Zhavania, N. Birdi, R.J. Cuttica, S.H.F. de Oliveira, P.B. Dent, R. Elborgh, F. Falcini, G. Ganser, H. Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, R. Russo, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian: Günstigere Überlebenschance bei 135 Patienten mit juveniler systemischer Sklerodermie (jSSc): Ergebnisse einer multinationalen Studie. 8. Jahrestagung der Arbeitsgemeinschaft für Kinder- und Jugendmedizin, 10/98 Cottbus.
I. Foeldvari., M. Redegeld, M. Mehrwald, D. Hülsebus, M. Bullinger. Gesundheitsbezogene Lebensqualität von Rheuma-betroffenen Kindern und Jugendlichen aus Elternsicht. Jahrestagung der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie und Pädiatrische Immunologie, Tübingen Mai 2000.
B. Finckh, I. Foeldvari, D. Huelsebus, M. Mehrwald, A. Kohlschütter: Changes of antioxidative status and lipid peroxidation in juvenile idiopathic arthritis over a period of three months. 10th Biennial Meeting of the International Society for Free Radical Research. Abstract No. 002-5 (Reference No.: 100) Kyoto, Japan, 10/2000.
G. Horneff, I. Foeldvari, R.M. Küster, H. Michles, D. Moebius, H. Schmeling, A. Thon: Etanercept for the treatment of juvenile idiopathic arthritis: results of the German registry. Ann Rheum Disease 2002, 61,Suppl 1: 52 – OP 0062.
I. Foeldvari: Steroid induzierte Osteoporose bei Kindern mit kinderheumatologischen Erkrankungen? Ergebnisse einer Pilotstudie. Zeitschrift für Rheumatologie, 2002, 61 (Suppl. 1.): I/64 (PDG 11)
I. Foeldvari: Es zeigt sich eine sehr gute Verträglichkeit von Vioxx? in der Anwendungsbeobachtung. 12. Jahrestagung der Arbeitsgemeinschaft für Kinder- und Jugendrheumatologie. Aktuelle Rheumatologie 2002, 27 :276 (36).
G. Horneff , T. Biedermann, I. Foeldvari, et al. Combination therapy with methotrexat and etanercept compared to etanercept monotherapy. Xth European Pediatric Rheumatology Congress. Clinical Experimental Rheumatology 2003, 21: 540
G. Martini, I. Foeldvari, R.Russo, et al. Juvenile systemic sclerosisand related disorders: an international multicentre data collection of 181 patients. Xth European Pediatric Rheumatology Congress. Clinical Experimental Rheumatology 2003, 21: 551
K. Minden, M. Niewerth, G. Ganser, RM Küster, D. Möbius, I. Foeldvari, A. Zink: Therapiekontinuität bei der juvenilen idiopathischen Arthritis. 13. Jahrestagung der Arbeitsgemeinschaft für Kinder und Jugendrheumatologie. Aktuelle Rheumatologie, 2003, 28: 282, F.6.
I. Foeldvari, A. Wierk. Results of leflunomide (LEF) therapy in patients with juvenile idiopathic arthritis (JIA): A pilot noncontrolled therapeutic intervention. EULAR 2004 , Berlin, Ann Rheum Dis 2004, 61 (Supll 1.): 80 – OP 0076.
I. Foeldvari, A. Wierk. Kann man in der pädiatrischen Population den modifizierten Rodnan Skin Score ohne Adaptation anwenden? Zeitschrift für Rheumatologie 2004, 63: 274- F.3.
N.Ruperto, DJ. Lovell, S. Goodmann, A. Reiff, L. Jung, D.Nmecova, K. Jarosova, AM: Prieur, C. Sandborg, R. Joos, I. Foeldvari, et,al. Preliminary data from the open label phase of he randomized trial of adalimumab in children with juvenile idiopathic arthritis. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:522.
I. Foeldvari, A. Wierk: Helathy children have a significantly increased skin score assessed with the modified Rodnan skin score. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:527.
N. Ruperto, A. Ravelli, S.Olivieri, E. Silverman, G. espada, D. Mihaylova, S. Pasic, S. Ozen, M. Apaz, B. Bica, D. nemcova, R. Burgos-Varagas, F. Corona, AM. Romicka, J. Consuegra, S. Hagleberg, C Da Silva, C. Coto, Y. Uziel, J. Ros, MI. Gamir, I. Foeldvari, et, al. The validated PRINTO core set and definition of improvement for juvenile systemic lupus erythematosus. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:510.
G. Horneff, R. Küster, H. Girschick, I. Foeldvari, D. Moebius. Safety of etanercept for treatment of juvenile idiopathic arthritis (JIA) – data of the German etanercept JIA registry. EULAR 2005, Wien , Österreich. Ann Rheum Dis 2005, 64 , Supplement III: 72 – OP 0048.
C. Boschau, O. Witt, L. Schweigerer, P. Lohse, I. Foeldvari, H. Zappel. Neonatal-onset multisystem inflammatory disease (NOMID): new mutation of the CIAS1 gene and response to interleukin-1 recptor antagonist treatment. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ3-3, I/29.
I. Foeldvari, S. Nielson, J. Kümmerle-Deschner, T. Sauerenman. Ergebnisse der multinationalen Befragung über die Anwendung der Tumor Nekrosis Faktor alpha Blocker in der Behandlung der JIA assoziierten Uveitis. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ3-7, I/30.
M. Niewerth, K. Minden, I. Foeldvari, G. Ganser, A. Zink. Übergewicht – ein Thema bei rheumakranken Kindern und Jugendlichen? Gewichtsstatus bei Patienten mit juveniler idiopathischer Arthritis. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ2-5, I/28.
F. Zulian, P. Woo, B.H. Athreya, R. laxer, T.A. Medsger, T.A. Lehman, M. Matucci-Cerinic, G. Martini, A. Ravelli, R. Russo, R. Cuttica, S.F.K. De Oliveira, C. Denton, I. Foeldvari, N. Ruperto. Preliminary classification criteria for systemic sclerosis in children. XII. European Pediatric Rheumatology Congress, Versaille, Frankreich 2005. Clinical Exp Rheumatol 2005; 23 (Suppl 37): S-47.
G. Horneff, H. Girschick, I. Foeldvari, H. Michels, B. Rogalski, H. Schmeling: Combination therapy with etanercept and methotrexate compared to etanercept monotherapy in patients with juvenile idiopathic arthritis. 2005 Annual Scientific Meeting of the American College or Rheumatology, San Diego, Ca., USA. Arthritis Rheum 2005, 52 (Suppl): A 1955.
N. Ruperto, D.J. Lovell, S. Goodman, A. Reiff, L.Jung, D: Nemcova, K. Jarosova, A. Prieur,C. Sanborg, R. Joos, I. Foeldvari, V. Gerloni, J. Rovensky, J. Bohnsack, K.Minden, L. Wagner-Weiner, R. Vehe, H. Huppertz, G. Horneff,N. Olson, J. Medich, E.H. Giannini, A. Martini: 48 week data from the study of adalimumab in children with juvenile rheumatoid arthritis. Annual European Congress of Rheumatology, 2006, Amsterdam, Holland. Ann Rheum Dis 2006, 65 Suppl II: 56.
I.Foeldvari, A. Heiligenhaus, C.Tappeiner,S. Nielson, N. Tzaribachev, J. Quitsch, F. Dressler, M.O. Hilario, R.M. Küster, M. Borte, H. Mazu, E. Jäger-Roman, A. Wierk: Ergebnisse einer mulitnationalen Befragung zur Anwendung von Cyclopsporinb-A (CSA) in der Behandlung von Uveitis assoziiert mit juvenilen idiopathischen Arthritis (JIA). 16. Jahrestagung der Gessellschaft für Kinder- und Jugendrheumatologie , Leipzig 2006. Kinder- und Jugendmedizin 2006; 6: A 50, Abstact 39.
G. Horneff, I. Foeldvari, J. Roth, H. Michels, M. Borte, H. Schmeling. Efficacy and tolerability of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. 2006 Annual Scientific Meeting of the American College of Rheumatology, Washington. Arth Rheumatism 2006, 54 (Suppl):S327 A 722.
O. Kowal-Bielecka, R. Landews, J. Avouac, S. Chwiesko, L. Miniati, L. Czirjak, P. Clements, C. Denton, D. Farge, K. Fligelstone, I. Foeldvari,… et al. EULA/EUSTAR recommendation for the management of systemic sclerosis. THU0281, EULAR 2007 Barcelona.
I. Foeldvari, C. Wotuers, T. Avcin, F. Zulian. Results of a multinationla survey regarding preferences of paediatric rheumatologists in the treatment of juvenile systemic sclerosis. OPO185, EULAR 2007, Barcelona.
F.Zulian, O.Kowal-Bielecka, I. Miniati, J. Avouac,SChwiesko, A. Aggarwal, BH Atreya, T. Avcin, R. Cuttica, SDKF de Oliveira, G. Higgins, RM Laxer, C. Lindsley, TH Lehman, G Martini, A Ravelli, R Russ, Y Uziel, C Wouters, I Foeldvari, EUSTR/Eular commitess on SSc management recommendations. Preliminary agreement of the Pediatric Rheumatology European Society(PRES) in the EUSTAR/EULAR redommendations for the management of systemic sclerosis in children. OP-17 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
I Foeldvari, C Wouters, T Avcin, F Zulian. Results of a multinational survey regarding preferences of paediatric rheumatologists in the treatment of juvenile systemic sclerosis. OP-19 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
I Foeldvari, A Wierk. Leflunomide is an effective alternative in the treatment for patients with juvenile idiopathic arthritis. OP-30 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
O Distler, D Pittrow, F Behrens, D Huescher, C Denton, I Foeldvari, et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphie consensus study with cluster analysis. ACR 2007, Boston. Arthritis Rheumatism 2007, 56 (Suppl): A 2164, S 824
I. Foeldvari. The prospective juvenile systemic sclerosis inceptions cohort. 1st Conference on Translational Research I Pediatric Rheumatology. Genoa , Italy.2008.
D Lovell, R Cuttica, P Woo, G Espada, C Wouters, ED Silverman, Z Balogh, M Henricksen, J Davidson, I Foeldvari, L Imundo, G Simonini, J Oppermann, YK Shen, S Visvanathan, A Fasanmade et al. Long term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course JRA: findings from the open label treatment extension. Annual PRES meeting London, UK 2008.
A randomised trial of 6 months versus 12 months withdrawal of methotrexate in children with juvenile idiopathic arthritis in clinical remission.. D. Foell, N. Wulffraat, L.R. Wedderburn, A. Pistorio, A. Ravelli, V. Stanevicha, D. Mihaylova, V.P.L. Ferriani, F. Kanakoudi Tsakalidou, I. Foeldvari, R. Cuttica, B. Gonzalez4, R. Khubchandani, S.K.F. Oliveira, W. Armbrust, S.M. Garay, J. Vojinovic, X. Norambuena, M. Gamir, J. Garcia Consuegra, L. Lepore, G. Susic, F. Corona4, P. Dolezalova, T. Saurenmann, Y. Uziel, A. Martini, N. Ruperto, for PRINTO
EULAR 2009 [THU0413], Copenhagen, Denmark.
N. Ruperto, D.J. Lovell, R. Mouy, E. Paz, N. Rubio-Perez, C.A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J.A. Melo-Gomes, C. Saad-Magalhaes, J. Chavez1, C. Huemer, A. Kivitz, F. Blanco, I. Foeldvari, M. Hofer, G. Horneff1, H. Huppertz, C. Job Deslandre, K. Minden, M. Punaro, A. Flores Nunez, L.H. Sigal, A.J. Block, A. Covucci, A. Martini, E.H. Giannini. Long-term safety and efficacy of abatacept in subjects with polyarticular juvenile idiopathich arthritis. OP- 0268 EULAR 2009 [THU0413], Copenhagen. Denmark.
J.B. Kuemmerle Deschner, R. Cartwright, M. Gattorno, F. Zulian, P. Quartier, J. Hoyer, I. Foeldvari, E. Ramos, P.N. Hawkins, K. Leslie, G. Krammer, S. Malfait, R. Preiss, A. Widmer and E. Hachulla. Safety and effecacy of canakinumab in children accross different disease severity and phenotypes of cryopyrin associated periodic syndrome (CAPS): intermin results of an ongoing study. ACR 2009 Philadelphia, USA, Arthritis Rheum 2009, 60: #2056.
P Quartier, E Hachulla, M Gattorno, R Cartwright, I Kone-Paut, F Zulian, E Weisbarth-Riedel, L Lepore, J Hoyer, I Foeldvari, E Ramos, P N Hawkins, K Leslie, G Krammer, R Preiss, A Widmer, J B Kuemmerle-Deschner. Canakinumab (ILARIS®) Provides Rapid Response and Sustained Remission in Children across Different Disease Severity Phenotypes of Cryopyrin Associated Periodic Syndrome (CAPS). ACR 2010. Arth Rheum 2010, 62.
I. Foeldvari, A. Wierk, D. Farge. When is autologous bone marrow transplantation indicated in juvenile systemic sclerosis. Results of a multinational survey of pediatric rheumatologist. 2 nd Systemic Sclerosis World Congress, 02.-04.2012, Madrid . Spain. Rheumatology 2012, Volume 51, Supplement 2; S1.4. ii2.
I Foeldvari . Looking for minimal standards in care of children with localised scleroderma. Resutls of the consensus meeting in Hambug Germany on the 11th of December 2011. DGRH 2012 Bochum
D. J. Lovell1, N. Ruperto2, R. Mouy2, E. Paz2, N. Rubio-Perez2, C. A. Silva2,C. Abud-Mendoza2, R. Burgos-Vargas2, V. Gerloni2, J. A. Melo-Gomes2, C ,Saad-Magalhaes2, J. Chavez2, C. Huemer2, A. Kivitz2, F. Blanco2, I. Foeldvari2, Michael Hofer3, H. Huppertz2, C. Job Deslandre2, K. Minden2, A. Flores Nunez4, A. J. Block5 and A. Martini2. 1Cincinnati Children’s Hospital, Cincinnati, OH, 2PRINTO, IRCCS G. Gaslini, Genoa, Italy, 3Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, 4PRINTO, IRCCS Hospital para el Nin˜o Poblano, Puebla, Mexico, 5Bristol-Myers Squibb, Princeton, NJ. Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up. Arth Rheum 2012, 64:S 717 A 1679
Seza Özen1, Jasmin Kuemmerle-Deschner2, Luca Cantarini3, Rolando Cimaz4, Pierre Quartier5, Ahmet Gül6, Isabelle Koné-Paut7, Steven Spalding8, Andrew Zeft8, Anna Simon9, Philip Hashkes10, Véronique Hentgen11, Tilmann Kallinich12, Sinisa Savic13, Ivan Foeldvari14, Joost Frenkel15, Uwe Machein16, Avi Livneh17, Helen J. Lachmann18. Patient Journey and Treatment Route to Use of First Biologic in Rare Autoinflammatory Diseases: An International Retrospective Chart Review. EULAR Annual Meeting Paris 2014.
Gerd Horneff*, Sophie Von Stackelberg, Ivan Foeldvari, J-P. Haas, Gerd Ganser, Kirsten Minden, Anton Hospach on behalf of the German and Austrian Collaborative BIKER study group. JADAS REMISSION AND MINIMAL DISEASE ACTIVITY UPON FIRST BIOLOGIC IN JIA. EULAR Annual Meeting Paris 2014.
Gerd Horneff, Ivan Foeldvari, Kirsten Minden, Klaus Tenbrock, Hans I. Huppertz, Ingrid Becker. ANALYSIS OF UVEITIS EVENTS IN THE BIOLOGICS IN PEDIATRIC RHEUMATOLOGY (BIKER)-REGISTRY. EULAR Annual Meeting Paris 2014.
N Ruperto,1 DJ Lovell,2 N Tzaribachev,3 G Vega-Cornejo,4 I Louw,5 A Berman,6 I Calvo,7 R Cuttica,8 G Horneff,9 F Avila-Zapata,10 J Anton,11 D Viola,12 I Foeldvari,13 V Keltsev,14 D Kingsbury,15 X Li,16 M Nys,17 R Wong,16 S Banerjee,16 A. Martini,18 HI Brunner2. Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety. EULAR Annual Meeting London 2016.
I Foeldvari* 1 , N Ruperto1 , DJ Lovell2 , G Horneff1 , H-I Huppertz1 , P Quartier3 , G Simonini1 , M Bereswill4 , J Kalabic4 , AMartini1 , HI Brunner2 UVEITIS ASSOCIATED TO POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): DATA FROM STRIVE REGISTRY. PRES Meeting Genua 2016.
Foeldvari¹, J. Klotsche², O. Kasapcopur³, A. Adrovic³, V. Stanevicha⁴, M.T. Terreri⁵, E. Alexeeva⁶, M.M. Katsicas⁷, R. Cimaz⁸, M. Kostik⁹, T. Lehman¹⁰, W. A. Sifuentes-Giraldo¹¹, V. Smith¹², F. Sztajnbok¹³, T. Avcin¹⁴, M. Jose Santos¹⁵, M. Moll¹⁶, D. Nemcova¹⁷, C. Battagliotti¹⁸, D. Eleftheriou¹⁹, H. Liora²⁰, M. Janarthanan²¹, T. Kallinich²², J. Lopez²³, K.Minden²², S. Nielsen²⁴, K. Torok²⁵, Y.Uziel²⁶, N. Helmus¹. CHARACTERISTICS OF THE FIRST 97 PATIENTS AT TIMEPOINT OF FIRST ASSESSMENT INCLUDED IN THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILESCLERODERMA.COM. DGRH , Stuttgart. 09.09.2017
Ivan Foeldvari, Jordi Anton, Marc Friswell, Blanca Bica, Jaime Innocencio, Rebecca Nicolai, Nicola Helmus. Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients. Annual PRES meeting, Athens 2017.
I. Foeldvari 1, J. Klotsche2, O. Kasapcopur3, A. Adrovic3, V. Stanevicha3, K. Torok3, T. Terreri3, E. Alexeeva3, M. Katsikas3, V. Smith3, F. Sztajnbok3, T. Avcin3, R. Cimaz3, J. Anton3, M. Kostik3, T. Lehman3, W.-A. Sifuentes-Giraldo3, S. Appenzeller3, M. Janarthanan3, M. Moll3, D. Nemcova3, M.J. Santos3, C. Battagliotti3, L. Berntson3, J. Brunner3, D. Eleftheriou3, L. Harel3, T. Kallinich3, K. Minden2, S. Nielsen3, Y Uziel3, A. Stevens3, C.Pilkington3, N. Helmus1. Are patients with overlap features different from patients without? Results from the juvenile systemic scleroderma cohort www.juvenile-scleroderma.com. American College of Rheumatology Meeting 2017, Nov 08. San Diego, USA.
S. Özen, E. Ben-Chetrit, I. Foeldvari, G. Amarilyo, H. Ozdogan, S. Vanderschueren, K. Marzan, J. M. Kahlenberg, E. Dekker, F. De Benedetti, I. Koné-Paut. LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL, OP 0272. EULAR 2020, 03.-06. June, Frankfurt, Germany (ECongress).
I. Foeldvari, J. Klotsche. Validation of Disease activity measures in patients with juvenile systemic sclerosis. Results from the inception cohort World Scleroderma Congress ECongress 12-14th of July, 2020.
J. B. Kuemmerle-Deschner, B. Kortus, Goetze, P. Oommen, A. Janda, J. Rech, T. Kallinich, F. Weller-Heinemann, G. Horneff, I. Foeldvari, C. Schuetz, M. Borte, A. Braner, J. Weber-Arden, N. Blank. OP0092 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) – 30-MONTH DATA FROM THE RELIANCE REGISTRY. EULAR 2021. E Congress 2-5th of June, 2021
I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, K. Torok, M. T. Terreri, A. P. Sakamoto, B. Feldman, V. Stanevicha, J. Anton, F. R. Sztajnbok, R. Khubchandani, E. Alexeeva, M. Katsikas, S. Sawhney, V. Smith, S. Appenzeller, T. Avcin, M. Kostik, T. Lehman, E. Marrani, D. Schonenberg, W. A. Sifuentes-Giraldo, N. Vasquez-Canizares, M. Janarthanan, M. Moll, D. Nemcova, A. Patwardhan, M. J. Santos, C. Battagliotti, L. Berntson, B. Bica, J. Brunner, R. Cimaz, P. Costa Reis, D. Eleftheriou, L. Harel, G. Horneff, S. Johnson, D. Kaiser, T. Kallinich, D. Lazarevic, K. Minden, S. Nielsen, F. Nuruzzaman, S. Opsahl Hetlevik, Y. Uziel, N. Helmus. POS0079 PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS HAVE A DISTINCT PATTERN OF ORGAN INVOLVEMENT.RESULTS FROM THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM,. EULAR 2021. E Congress 2-5th of June, 2021
N. Ruperto, G. Schulert, A. Sproles, S. Thornton, G. Vega Cornejo, J. Anton, R. Cuttica, M. Henrickson, I. Foeldvari, D. Kingsbury, M. Askelson, J. Liu, S. Mukherjee, R. Wong, D. J. Lovell, A. Martini, A. Grom, H. Brunner. POS0076 S100A8/A9 AND S100A12 AS POTENTIAL PREDICTIVE BIOMARKERS OF ABATACEPT RESPONSE IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. EULAR 2021. E Congress 2-5th of June, 2021
A. Zimmer, A. Klein, K. Minden, T. Hospach, F. Weller-Heinemann, J. Kuemmerle-Deschner, M. Fasshauer, N. Hofmann, H. Koessel, I. Foeldvari, S. Mrusek, D. Windschall, N. Onken, M. Hufnagel, D. Foell, N. Brueck, P. T. Oommen, F. Dressler, A. Helling-Bakki, G. Horneff. POS0075 SAFETY AND EFFICACY OF GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS – AN UPDATE FROM THE BIKER REGISTRY. EULAR 2021. E Congress 2-5th of June, 2021
N Ruperto1*, I Foeldvari2, E Alexeeva3, N A Ayaz4, I Calvo5, O Kasapcopur4, V Chasnyk6, M Hufnagel7, Z Zuber8, G Schulert9, S Ozen10, A Popov11, A Ramanan12, C Scott13,
B Sozeri14, E Zholobova15, X Zhu16, S Whelan17, L Pricop16, A Ravelli18, A Martini1,
D J Lovell19, H I Brunner19 on behalf of PRINTO and PRCSG. Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA). EULAR 2021. E Congress 2-5th of June, 2021
N Ruperto1*, I Foeldvari2, E Alexeeva3, N A Ayaz4, I Calvo5, O Kasapcopur4, V Chasnyk6, M Hufnagel7, Z Zuber8, G Schulert9, S Ozen10, A Popov11, A Ramanan12, C Scott13,
B Sozeri14, E Zholobova15, X Zhu16, S Whelan17, L Pricop16, A Ravelli18, A Martini1,
D J Lovell19, H I Brunner19 on behalf of PRINTO and PRCSG. Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA). PRES Virtual Congress . 19.-21.09.2021
Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic3, Maria Teresa Terreri4, Ana Paula Sakamoto4, Valda Stanevicha5, Jordi Anton6, Brian M. Feldman7, Flavio Sztajnbok8, Raju Khubchandani9, Ekaterina Alexeeva10, Maria Katsicas11, Sujata Sawhney12, Vanessa Smith13, Simone Appenzeller14, Tadej Avcin15, Mikhail Kostik16, Thomas Lehman17, Edoardo Marrani18, Dieneke Schonenberg-Meinema19, Walter-Alberto Sifuentes-Giraldo20, Natalia Vasquez-Canizares21, Mahesh Janarthanan22, Monika Moll23, Dana Nemcova24, Anjali Patwardhan25, Maria Jose Santos26, Cristina Battagliotti27, Lillemor Berntson28, Blanca Bica29, Jürgen Brunner30, Rolando Cimaz31, Patricia Costa-Reis32, Despina Eleftheriou33, Liora Harel34, Gerd Horneff35,36, Sindhu R. Johnson37, Daniela Kaiser38, Tilmann Kallinich39, Dragana Lazarevic40, Kirsten Minden39, Susan Nielsen41, Farzana Nuruzzaman422, Siri Opsahl Hetlevik43, Yosef Uziel44, Nicola Helmus1, Kathryn S. Torok45. Male juvenile systemic sclerosis patients have more severe disease: results from the international juvenile scleroderma inception cohort. PRES Virtual Congress . 19.-21.09.202
Ivan Foeldvari2, Bernd Hinrichs1, Ekaterina Alexeeva3, Jordi Anton3, Simone Appenzeller3, Lillemor Berntson3, Jürgen Brunner3, Patricia Costa Reis3, Brian Feldman3, Gerd Horneff3, Mahesh Janarthanan 3, Tilmann Kallinich3, Ozgur Kasapcopur3, Raju Khubchandani3, Mikhail Kostik3, Thomas Lehman3, Edoardo Marrani3, Susan Nielsen3, Farzana Nuruzzaman3, Anjali Patwardhan3, Maria Jose Santos3, Dieneke Schonenberg-Meinema3, Vanessa Smith3, Valda Stanevicha3, Flavio Sztajnbok3, Maria Teresa Terreri3, Kathryn Torok3, Yosef Uziel 3, NIcola HelmusHOW IS PULMONARY FUNCTION ASSESSED IN JUVENILE SYSTEMIC SCLERODERMAPATIENT? DO WE HAVE A GOOD CLINICAL STANDARD? RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT- WWW.JUVENILE-SCLERODERMA.COM. PRES Virtual Congress . 19.-21.09.2021
Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic3, Kathryn Torok3, Maria T. Terreri3, Ana Paula Sakamoto3, Flávio R. Sztajnbok3, Brian Feldman3, Valda Stanevicha3, Jordi Anton3, Raju Khubchandani3, Ekaterina Alexeeva3, Sindhu Johnson3, Maria Katsikas3, Sujata Sawhney3, Vanessa Smith3, Simone Appenzeller3, Tadej Avcin3, Mikhail Kostik3, Thomas Lehman3, Edoardo Marrani3, Dieneke Schonenberg-Meinema3, Walter Alberto Sifuentes-Giraldo3, Natalia Vasquez-Canizares3, Mahesh Janarthanan3, Hana Malcova3, Monika Moll3, Dana Nemcova3, Anjali Patwardhan3, Maria Jose Santos3, Cristina Battagliotti3, Lillemor Berntson3, Blanca Bica3, Juergen Brunner3, Rolando Cimaz3, Patricia Costa Reis3, Despina Eleftheriou3, Liora Harel3, Gerd Horneff3, Daniela Kaiser3, Tilmann Kallinich3, Dragana Lazarevic3, Kirsten Minden2, Susan Nielsen3, Farzana Nuruzzaman3, Siri Opsahl Hetlevik3, Yosef Uziel3, Nicola Helmus1 Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement results from the juvenile systemic sclerosis inception cohort. . PRES Virtual Congress . 19.-21.09.2021
Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic3, Maria Teresa Terreri4, Ana Paula Sakamoto4, Valda Stanevicha5, Jordi Anton6, Brian M. Feldman7, Flavio Sztajnbok8, Raju Khubchandani9, Ekaterina Alexeeva10, Maria Katsicas11, Sujata Sawhney12, Vanessa Smith13, Simone Appenzeller14, Tadej Avcin15, Mikhail Kostik16, Thomas Lehman17, Edoardo Marrani18, Dieneke Schonenberg-Meinema19, Walter-Alberto Sifuentes-Giraldo20, Natalia Vasquez-Canizares21, Mahesh Janarthanan22, Monika Moll23, Dana Nemcova24, Anjali Patwardhan25, Maria Jose Santos26, Cristina Battagliotti27, Lillemor Berntson28, Blanca Bica29, Jürgen Brunner30, Rolando Cimaz31, Patricia Costa-Reis32, Despina Eleftheriou33, Liora Harel34, Gerd Horneff35,36, Sindhu R. Johnson37, Daniela Kaiser38, Tilmann Kallinich39, Dragana Lazarevic40, Kirsten Minden39, Susan Nielsen41, Farzana Nuruzzaman422, Siri Opsahl Hetlevik43, Yosef Uziel44, Nicola Helmus1, Kathryn S. Torok45. Male juvenile systemic sclerosis patients have more severe disease: results from the international juvenile scleroderma inception cohort. Kongress der Deutschen Gesellschaft für Kinder- und Jugendrheumatologie. Berlin, 06-09.10.2021
Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent SHARE consensus guidelines. Deutsche Rheumatologiekongress 2022, 31.08.-03.09.2022, Berlin, Germany.
Safety and Efficacy of Upadacitinib for Pediatric Patients With Polyarticular Course Juvenile Idiopathic Arthritis: An Interim Analysis of the Open-label, Phase 1 Trial. Hermine I Brunner1, Gerd Horneff2,3, Ivan Foeldvari4, Jordi Anton5, Mohamed-Eslam F . Mohamed6, Yuli Qian6, Kristina Unnebrink7, Shuai Hao6, Heidi Camp6, Nasser Khan6, Anna Shmagel6. EULAR. Milano, Italy, 2023
Horneff G, Zimmer A, Hospach A, Weller-Heinemann F, Kuemmerle-DeschnerJ, Fasshauer M, Minden K, Foeldvari I, RietschelC, Windschall D, Trauzeddel R, Hufnagel M, FoellD, Berendes R, BoeschowR, OommenPT, Dressler F, Klein A.24 month results on effectiveness and safety of a comparative study of tocilizumab versus tumournecrosis factor inhibition in idiopathic arthritis. EULAR. Milano, Italy, 2023
Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 24 months observation period in the juvenile systemic scleroderma inception cohort .www.juvenile-scleromderma.com. Deutscher Rheumatologie Kongress, 01.09.23, Leipzig. Germany
Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have significantly more severe disease in the largest jSSc cohort of the world
www.juvenile-scleromderma.com. Deutscher Rheumatologie Kongress, 01.09.23, Leipzig. Germany
WIRKSAMKEIT UND SICHERHEIT VON SECUKINUMAB BEI JUVENILER IDIOPATHISCHER ARTHRITIS: Interimsergebnisse aus der Verlängerung der JUNIPERA-Studie. Deutscher Rheumatologie Kongress, 01.09.23, Leipzig. Germany
Application of CRISS score, revised CRISS score and RCID score in patients with diffuse cutaneous Juvenile systemic sclerosis. Jens Klotsche*1, Ivan Foeldvari2, Kathryn Torok3, et al.. Deutscher Rheumatologie Kongress, 01.09.23, Leipzig. Germany

Letters

I. Foeldvari : Regarding the possible association of juvenile rheumatoid arthritis, Crohn’s disease and Turner’s syndrome. Letter to the editor. Clin Exp Rheumatol 1997; 15: 120.
I. Foeldvari: Progressive linear scleroderma and morphea in a child. Insights in Pediatrics. J Pediatrics 1988;133:308.
I. Foeldvari: Results of the multinational survey regarding feasibility-study for a therapeutic trial in juvenile systemic sclerosis. Letter. Clinical and Experimental Rheumatology 2000,18: 424.
I. Foeldvari : Do we need a pediatric rheumatologist? – The Hamburg Experience. Letter to the editor. Arth Rheumatism 1999,42:396.
I. Foeldvari: Anti-keratin antibodies in patients with JIA. Letter. Clin Exp Rheumatol 2001;19:762.
I. Foeldvari: A selective COX-2 inhibitor, meloxicam, as treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen. Letter. Clinical Exp Rheumatol 2002,20:874.
I. Foeldvari, T. Schneider: Acute, non-obstructive, sterile cholecystitis associated with Etanercept and Remicade for the treatmetn of juvenile polyarticular rheumatoid arthritis. Annals of Rheum Dis 2003, 62: 908-909.
I. Foeldvari, A. Wierk. Methotrexate and chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2006, 33: 198 – Impact factor – 3,551
Poff1, SC Li2, CE Kelsey1, I Foeldvari3, KS Torok1. Durometry as an Outcome Measure in Juvenile Localized Scleroderma. British Journal of Dermatology, accepted 2015. BJD-2014-2188.R1
Maurizio Cutolo1,*, Karin Melsens2,3,*, Ariane L. Herrick4, Ivan Foeldvari5 Deschepper6 , Filip De Keyser2,3, Oliver Distler7 , Francesca Ingegnoli8 , Yora Mostmans9,10,11, Ulf Mu¨ ller-Ladner12,13, Carmen Pizzorni1 , Valeria Riccieri14, Barbara Ruaro1 , Alberto Sulli1 , Amelia C. Trombetta1 , Amber Vanhaecke2,3 and Vanessa Smith2,3; for the EULAR Study Group on Microcirculation in Rheumatic Diseases. Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. Rheumatology 2018, 57:757-759
Uwe Pleyer, Jens Klotsche, Ivan Foeldvari, Kirsten Minden, arnd heiligenhaus. Adalimumab in JIA-uveitis. Ophthalmology. 10th of January 2019 OPHTHA_2018_2741_R1
Ivan Foeldvari1, Bernd Hinrichs2, Kathryn S. Torok3, Franziska Rosser4, Nicola Helmus1, jSSc collaborative group5*. HOW IS PULMONARY FUNCTION ASSESSED IN PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS? DO WE HAVE A GOOD CLINICAL STANDARD? Results from the juvenile systemic sclerosis inception cohort. J Rheumatol accepted 7th of March.2023.